



PASPCR

Newsletter

Volume 4 Number 1

March, 1996

Introduction . . .

by the Publications Committee

The *PASPCR Newsletter* is published quarterly and is intended to serve as a means of communication for the members of our Society. As such, we invite our membership to actively contribute to the *Newsletter*; help us to update the Job Listings, Calendar of Events, Meeting Reports, Abstracts in press and other items of general membership interest. If you attend a scientific meeting at which you heard about work which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. If you should have a change of affiliation or address, we'd like to know that, too. This is **your Newsletter**, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to any of the members of the Publications Committee.

NEW! A WorldWideWeb Page for the PASPCR. The PASPCR now has its own **WWW** page. We plan this to be a major source of current information for the PASPCR membership. The address for the page is: <http://lenti.med.umn.edu/paspcr>. This site contains information on the goals of the society, future meetings, council information, past issues of the PASPCR newsletter as well as links to other sites including the InterPig data base and the International Federation of Pigment Cell Societies (IFPCS). We will be also finalizing the membership directory. You should soon receive a mailing that will allow you to state what information about yourself that you want included in this directory. This will be an important part of this web site, in that changes in the membership directory can be easily made, providing access to up to date membership information. The PASPCR WWW page is still under construction and we want to know if there is any other information you would like located on this site.

Please check out the PASPCR web site and send any comments and/or suggestions to either Bill Oetting at bill@lenti.med.umn.edu or Vince Hearing at hearingv@dc37a.nci.nih.gov.

IN THIS ISSUE

Introduction	p 1
PASPCR Contact Information	p 2
Calendar of Events	p 2
Welcome to New Members	p 3
Corporate Sponsors	p 3
1995 PASPCR Election Results	p 3
In Memoriam ... Takuji Takeuchi	p 3
1996 XVI th Intl Pigment Cell Conf	p 4
Letter from the President	p 5
PASPCR Secretary/Treasurer's Report	p 6
Positions Wanted / Available	p 7
INTERPIG Update	p 7
Meeting Report - 10 th JSPCR	p 7
Bibliography	p 9
News & Views from the ESPCR	p 20
Membership List	p 24

enclosure: IPCC Travel Stipend Form

c/o **Dr. James J. Nordlund**
Department of Dermatology
University of Cincinnati
231 Bethesda Avenue
Cincinnati, OH 45267-0592
FAX: (513) 558-0198

Officers

Sally Frost-Mason
President
Richard A. King
President-Elect
James J. Nordlund
Secretary/Treasurer

Council Members

Raymond E. Boissy
Alan N. Houghton
Gert M. Jacobsohn
Kenneth A. Mason
Frank L. Meyskens, Jr.
David A. Norris
William S. Oetting
Dewayne Townsend
Walter C. Quevedo, Jr.

IFPCS Representative

Vincent J. Hearing
Past-President

The **PASPCR Newsletter** is published quarterly; for further information and/or to submit articles, contact the:

Publications Committee:

Dr. William S. Oetting

University of Minnesota
16-262 Moos Tower
515 Delaware St., S.E.
Minneapolis, MN 55455-0311
FAX: (612) 626-4027
E-mail: BILL@LENTI.MED.UMN.EDU

April 20 - 24, 1996 87th Annual Meeting of the American Association for Cancer Research, to be held in Washington DC (contact: AACR Office, Public Ledger Bldg, suite 816, 150 South Independence Mall West, Philadelphia PA 19106-3483; FAX: 215/440-9313)

May 1 - 5, 1996 57th Annual Meeting of the Society for Investigative Dermatology, to be held in Washington DC (contact: SID Office, Suite 500A, 11001 Cedar Ave, Cleveland, OH 44106; FAX: 216/844-6810)

June 2 - 6, 1996 Annual Meeting of the American Society for Biochemistry and Molecular Biology and the American Association of Immunologists, to be held in New Orleans, LA (contact: FASEB Office, 9650 Rockville Pike, Bethesda, MD 20814-3998; FAX: 301/530-7014)

Oct 29- Nov 3, 1996 XVIth International Pigment Cell Conference, to be held in Anaheim, California, (contact: MMC/UCI Center for Health Education, PO Box 1428, Long Beach, CA 90801-1428, FAX: 310/933-2012)

Dec 7 - 11, 1996 36th Annual Meeting of the American Society for Cell Biology and 6th International Congress on Cell Biology, to be held in San Francisco, CA, (contact: ASCB Secretariat, 9650 Rockville Pike, Bethesda, MD 20814-3992; FAX: 301/530-7139)

Jun 15- 18, 1997 VIIth PASPCR Annual Meeting, to be held in Providence, RI (contact: Dr. Walter C Quevedo, Jr., Brown University, Division of Biology and Medicine, Providence, RI 02912; FAX: 401/863-1971)

Welcome to New Members

by James J Nordlund / Richard A King

We welcome the following new member to the PASPCR . . .
Yiqing Xu

If anyone is interested in joining our Society or wishes to sponsor a member, application forms can be obtained from Dr. James J. Nordlund at the PASPCR Secretary/Treasurer's office.

Corporate Sponsors

by James J Nordlund / Richard A King

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

GOLD Corporate Patrons

ICN Pharmaceuticals, Inc
Lawrence M Gelb Research
Foundation of Clairol, Inc
Ortho Pharmaceutical Corp

SILVER Corporate Patrons

Avon Products, Inc
Chesebrough-Pond's USA Co
Procter and Gamble Co
Shiseido Co, Ltd

Corporate Patrons

Galderma Laboratories, Inc
Stiefel Laboratories

1995 PASPCR Elections

by Richard A King

The PASPCR elections are complete. Following are the results.

President-Elect:	Richard A. King		
Secretary/Treasurer:	James J. Nordlund		
Council members:	Kenneth Mason	Frank Meyskens	David A. Norris

In Memoriam . . . Dr. Takuji Takeuchi

by Shosuke Ito and Jiro Matsumoto

Dr. Takuji Takeuchi, Editor-in-Chief for *Pigment Cell Research*, died of liver failure on January 2, 1996. He was in the position of President of Nihon Gene Research Laboratories in Sendai and Professor of Ishinomaki Senshu University in Ishinomaki, Japan.

He was born in Kagawa Prefecture, Japan in 1930, graduated from Tohoku University in Sendai in 1955 and, via the Graduate School of Science there, appointed as Assistant Professor of Fukushima Prefectural Medical College in Fukushima in 1958. He stayed in the Department of Zoology at Rochester University from 1960 - 1961 and at the Department of Genetics (Professor M. Foster's laboratory) at the University of Michigan from 1961 - 1963.

After his return to Japan, he became Associate Professor of Miyagi University of Education in Sendai in 1965 and moved to Tohoku University in 1970. He was promoted to Professor in 1979 and became Professor of Animal Embryology there in 1985. In 1993 he retired at the age of 63 according to the age-limit system of Tohoku University.

Dr. Takeuchi dedicated himself to the organization of the XIth IPCC held in Sendai in 1980, together with the late Professor Makoto Seiji. He also organized the Symposium on Molecular Biology of Pigment Cells which was held in Sendai in 1990. He received the Seiji Award in 1984, the Zoological Society Prize from the Zoological Society of Japan in 1992, and the Myron Gordon Award from the IFPCS in 1993.

Dr. Takeuchi was a member of the Board of Associate Editors after the foundation of *Pigment Cell Research* in 1987 and was nominated as the successor of Professor Joseph T. Bagnara, the founding Editor-in-Chief, by recommendation of the IFPCS. The Japanese Government conferred the Order of Secret Treasure (Gold) with Neck Ribbon on him after his death.

XVIth IPCC (International Pigment Cell Conference) by Roger Bowers, Frank Meyskens

The XVIth International Pigment Cell Conference will be held from October 29th to November 3rd, 1996 at the Disneyland Hotel in Anaheim, California. Frank Meyskens is the Organizer of this meeting with Roger Bowers and Alistair Cochran serving as co-chairs of the Organizing Committee. The PASPCR has established a Web page that contains relevant information for this meeting; take a look at: "<http://lenti.med.umn.edu/paspcr/ipcc.htm>". Travel stipends for PASPCR members will be available as usual and a Travel Stipend Application Form with Instructions and Eligibility Requirements is included within this Newsletter. Following is the tentative Program of the IPCC:

XVIth International Pigment Cell Conference - Tentative Conference Agenda

Tuesday, October 29, 1996

3:00 - 7:00 pm Pre-registration/View Exhibits
 7:00 - 10:00 pm Welcome Reception: Fashion Show: "*Safe and Sexy in the Sun*"

Wednesday, October 30, 1996 Conference Attendees

7:00 - 8:00 am Registration/Continental Breakfast/View Exhibits
 8:00 - 8:05 am Welcome: Chairman, Frank L. Meyskens, Jr.
Introduction: Laurel Wilkening, Chancellor, Univ of California, Irvine
 8:05 - 8:35 am *Special Lecture*, R. Sherwood Rowland, Nobel Laureate, 1995, Chemistry
 "*Ozone Depletion, Ultraviolet Light, and the Pigment Cell*"
Symposium I: Economic and Societal Implications of Melanin and Melanogenesis
 8:35 - 9:00 am Keynote Speaker
 9:00 - 10:30 am Invited and Competitive Abstract Speakers
 10:30 - 11:00 am Break
 11:00 - 12:30 pm *Workshop A: "Extracutaneous Melanin"*
 Posters and Discussion #1 TBN* (11:00 - 12:00 Viewing; 12:00 - 12:30 Discussion)
 12:30 - 2:00 pm Lunch on your own

Symposium II: Molecular Biology of Pigment Cells

2:00 - 2:30 pm Keynote Speaker
 2:30 - 4:00 pm Invited and Competitive Abstract Speakers
 4:00 - 4:05 pm IFPCS InterPig Database on the WorldWideWeb: Vincent Hearing
 4:05 - 4:15 pm Break
 4:15 - 6:15 pm *Workshop B: "Regulating Mechanisms of Melanocyte Proliferation"*
 4:15 - 6:00 pm Posters and Discussion #2 TBN* (4:15 - 5:30 Viewing; 5:30 - 6:00 Discussion)
 5:30 - 7:00 pm *Workshop C: "Biophysics of Melanin"*
 6:15 pm Adjourn Free evening

Accompanying Guests (8:00 - 11:00 am) Welcome/Introduction: Buffet Breakfast;
 (12:00 - 5:00 pm) Group Activity

Thursday, October 31, 1996

7:00 - 8:00 am Continental Breakfast/View Exhibits
 8:00 - 8:30 am *Seiji Lectureship*: Introduction: Giuseppe Prota, President, IFPCS

Symposium III: Melanoma Research: Basic and Applied

8:30 - 9:00 am Keynote Speaker
 9:00 - 10:30 am Invited and Competitive Abstract Speakers
 10:30 - 11:00 am Break

11:00 - 12:30 pm **Workshop D: "Control of Melanogenesis"**
11:00 - 12:30 pm Simultaneous Business Meetings of Regional Societies
12:30 - 2:00 pm Lunch on your own

Symposium IV: Photobiology of Melanocytes: Etiology and Prevention

2:00 - 2:30 pm Keynote Speaker
2:30 - 4:00 pm Invited and Competitive Abstract Speakers
4:00 - 7:00 pm **Workshop E: The "Blues" Symposium**
4:00 - 7:00 pm Poster Viewing
Adjourn - Free evening

Friday, November 1, 1996

7:00 - 8:00 am Continental Breakfast/View Exhibits
8:00 - 8:30 am Introduction: Sally Frost-Mason, *President*, PASPCR
Gelb Lectureship: Seth Orlow

Symposium V: Melanogenesis and Pigmentary Disorders

8:30 - 9:00 am Keynote Speaker
9:00 - 10:30 am Invited and Competitive Abstract Speakers
10:30 - 11:00 am Break
11:00 - 12:30 pm **Workshop F: "Biology and Biochemistry of Melanosomes"**
11:00 - 12:30 pm Posters and Discussion #3 TBN* (11:00 - 12:00 Viewing; 12:00 - 12:30 Discussion)
12:30 - 1:15 pm **Controversy Session: "Semiquinone Radicals are not Important during Melanin Synthesis"**
Pro: Patrick Riley Con: Stan Pavel
1:15 pm Adjourn Scientific Session
1:15 - 6:30 pm Break
6:30 - 7:30 pm Reception
7:30 - midnight Banquet, Awards and Dancing

Saturday, November 2, 1996

7:00 - 8:00 am Continental Breakfast/View Exhibits
8:00 - 8:30 am **Presidential Address:** Giuseppe Prota, President IFPCS

Symposium VI: Comparative Developmental Biology of Pigment Cells

8:30 - 9:00 am Keynote Speaker
9:00 - 10:30 am Invited and Competitive Abstract Speakers
10:30 - 11:00 am Break
11:00 - 12:30 pm **Workshop G: "Genetic Aspects of Albinism"**
11:00 - 12:30 pm Posters and Discussion #4 TBN* (11:00 - 12:00 Viewing; 12:00 - 12:30 Discussion)
12:30 - 2:00 pm Lunch on your own
2:00 - 4:00 pm **Educational Forum: "Living with the Sun"**
4:00 - 6:00 pm Family Farewell Reception and Wine Tasting

Sunday, November 3, 1996

8:00 - 5:00 pm
1. *Satellite Meeting (all day): Classification of Cutaneous Melanoma:* Alistair Cochran
2. *Satellite Meeting (3 hours): Safety of Sunscreens and Tanning Parlors:* J.P. Césarini, et al.
3. *Satellite Meeting (3 hours): Ocular Melanin:* Giuseppe Prota

Workshops and poster and poster discussion sessions will be simultaneous. The poster sessions and discussions will feature areas that do not overlap with the workshop. The chairs of these sessions will be selected from submitted competitive abstracts and the Chairman in turn will organize this session with help from the Organizing Committee.

A Letter from the President :

by Sally Frost-Mason

Dear Members,

Please accept my heartfelt best wishes for a happy, safe, and productive new year. With the new year come changes in the Society. Vince Hearing who has so ably and unselfishly served three years as President, now assumes the role of Past President. Dick King, who has capably managed the Society's treasury since its inception, will be succeeded by Jim Nordlund. Dick will not be without responsibilities as he begins a term as President-Elect. New Council members include Frank

Meyskens, David Norris, and Ken Mason. Clearly, the Society remains in good hands as we look toward the millenium.

This year will be a year in which we celebrate our own successes at the International Pigment Cell Meeting in Anaheim, California in the fall. Frank Meyskens, Alistair Cochran, Roger Bowers and others have worked hard to ensure an outstanding scientific platform in one of the world's foremost playgrounds. Our Society can be pleased and proud of the quality that our meetings have always achieved, and we must all support the efforts in Anaheim as hosts to the rest of the Federation.

In the summer of 1997 we can look forward to PanAmerican meeting in Providence, Rhode Island. Walt Quevedo has already begun the planning process, so be sure and set aside time now to visit beautiful New England in June 1997.

A Society is only as viable as its membership. We have indeed been blessed with a loyal and hard-working membership. It is my hope that our membership can continue to grow in the coming years, and one of my primary goals will be to continue to find ways to both encourage and reward our young investigators, including faculty, postdocs, and students.

Finally, as we look toward the uncertainty of funding for basic research especially at the federal level, we must be ever vigilant in our efforts to support each other. I believe it is this spirit of cooperative endeavor that has sustained the vitality of our Society, and I know from speaking with visitors to our meetings that the mutual respect and support that we all derive from each other is both envied and greatly appreciated.

Once again, I thank you all for your support and I look forward to serving as your president for the next three years.

Sincerely, Sally Frost-Mason

PASPCR Secretary / Treasurer's Report :

by Richard A King

Following is a synopsis of the PASPCR Council Meeting held by teleconference on October 19, 1995 . . .

Hearing opened the meeting and a quorum was declared present. The minutes of the June 25, 1995, council meeting were unanimously approved.

Oetting, chair of the Publications Committee, discussed the WWW information site for the PASPCR and the newsletter, and reviewed the potential data that could be included in the web site including the name, method of contact and a short paragraph of research and publications. A questionnaire will be included with the upcoming ballot and dues notice surveying the membership on potential participation in the PASPCR web site. The Council discussed the lack of development of the membership brochure; this project will be turned over to a new committee.

Hearing reviewed the recent discussions and concerns regarding the 1996 IPCC Anaheim meeting. He noted that the officers of the society had met by telephone conference with Frank Meyskens, Roger Bowers and Alistair Cochran to express their interest in having continued regional society involvement in the development of the meeting, and Meyskens reassured the officers that this was planned. The IFPCS council will meet in Japan in early December and further discussion of regional society involvement in the development of the 1996 IPCC is expected.

Quevedo reviewed the plans for the 1997 PASPCR meeting in Providence, Rhode Island. Harold Swartz and Quevedo are organizing the program committee, and they have outlined three potential themes for the meeting: Cell suicide and apoptosis, development regulation and function of ocular pigment, and molecular genetics of melanoma models. Fund raising for this meeting continues to be a concern.

The minutes have been prepared by R. King, Secretary-Treasurer

Positions - Wanted and Available :

Predocutorial Position - Opportunity available to do graduate studies towards a doctoral degree at the University of Cincinnati College of Medicine. Graduate program is through the Department of Cell Biology, Neurobiology, & Anatomy. Dissertation project would focus on molecular biology of the melanocyte physiology and pigmentary diseases. For information contact: Raymond E. Boissy, Ph.D., Department of Dermatology, University of Cincinnati College of Medicine, 231 Bethesda Avenue ML-592, Cincinnati, Ohio 45267-0592; (513)558-6242 [TEL]; (513)558-0198 [FAX]; boissyre@ucbeh.san.uc.edu [eMAIL].

Faculty Position - Massachusetts General Hospital, Harvard Medical School, Cutaneous Biology Research Center. The Cutaneous Biology Research Center (CBRC) seeks a molecular, cellular or developmental biologist to establish a program in fundamental research relevant to skin pigmentation. Areas of research can include but are not limited to pigment synthesis and transfer in melanocytes, genetics of mouse coat color and development/migration of neural crest cells. Applicants must have a Ph.D. and/or M.D. degree and relevant postdoctoral experience. Only applicants with a strong research record and the potential to develop extramurally supported research programs will be considered. Individuals with a demonstrated ability to develop imaginative approaches to important biological questions are particularly encouraged to apply. Rank/salary/start-up funds and space are negotiable depending on experience and qualifications. The CBRC occupies 45,000 square feet of fully equipped laboratory space in a new multidisciplinary research facility. Interested individuals should send curriculum vitae, reprints, a statement of research and future directions, along with the names, addresses and telephone numbers of three references to: Dr. Paul F. Goetinck, Chair, Faculty Search Committee, Cutaneous Biology Research Center, Massachusetts General Hospital - East, Building 149, 13th Street, Charlestown, MA 02129

Director, Section of Basic Science Research - the Department of Dermatology and the Research Institute of the Cleveland Clinic Foundation are seeking applications for a full-time research scientist. Candidates should possess an M.D. and/or Ph.D. degree and have research experience in one of the following areas: wound healing, keratin/collagen biochemistry, or cancer immunology/molecular biology. The successful candidate will have the ability to work as an independent investigator and be the focus for dermatological research in a dynamic, multi-disciplinary and supportive environment. Preference will be given to individuals who have demonstrated prior success in obtaining extramural support. Salary and title will be commensurate with training and experience. A University affiliation is available. Send C.V. to: Charles Camisa, M.D., Vice-Chair, Department of Dermatology, A61, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195-5032.

INTERPIG DataBase Update

by Vincent Hearing

The INTERPIG database is on the InterNet! You can now access the InterPig DataBase at the following address: <http://lenti.med.umn.edu/paspcr/interpig.html>. Please note that as of this time, I estimate that less than 5% of the various IFPCS members have contributed entries. Think of how useful and complete this list would be if everyone took the time to supply their own information. Please take a moment to fill out the database data entry form and send it back to Dr. Hearing (a copy of the entry form is inserted into this Newsletter, and it can be photocopied).

Meeting Report

by Koichiro Kameyama

10th Annual Meeting of the J S P C R Osaka, Japan December 9-10, 1995

This meeting was organized by Osaka University School of Medicine with Prof. Morita as Chairman; it was composed of six special lectures by council members of IFPCS and 25 papers.

Special lecture "Modulation of expression and activity of tyrosinase, tyrosinase-related proteins and other melanosomal proteins in murine melanocytes treated with MSH or agouti signal protein" Dr. Vincent J. Hearing discussed the interaction of tyrosinase gene family products and MSH or agouti signal protein (ASP). Recently ASP has been reported to antagonize the ability of MSH using a cloned MSH receptor, and

ASP and MSH are key substances of the switching between eumelanogenesis and pheomelanogenesis. To further characterize the switch between eumelanogenesis and pheomelanogenesis, Dr. Hearing studied the responses of cultured melan-a black melanocytes exposed to MSH and/or recombinant ASP. After exposure to ASP, the color of the cell pellets changed from black to light brown, the number of melanosomes decreased, they became pheomelanosome-like at the ultrastructural level, and the amount of total melanin or eumelanin was much decreased, while the amount of pheomelanin was slightly but significantly increased. At the same time the amount of tyrosinase, TRP1 or TRP2 were decreased at mRNA level or protein synthesis level. When MSH was added to the culture, the amount of tyrosinase was increased at transcriptional level or translational level, and total melanin was increased due to increasing eumelanin, while the amount of pheomelanin was not changed significantly. Interestingly, in cells treated with MSH and ASP, the level of tyrosinase, TRP1, TRP2 and melanin production was increased. These data suggest that ASP suppress tyrosinase, TRP1 and TRP2 expression primary at the level of transcription and that the effects of ASP are not mediated solely by inhibition of MSH binding. After his lecture, there was one interesting question which asked the mechanism of the interaction between ASP and MSH. He answered that agouti is a functional antagonist of MSH binding and the possible mechanism is that; 1) via competitive inhibition of MSH binding, 2) via distinct agouti receptor, 3) via distinct effect on MSH receptor, and to resolve the question completely, further study such as binding study is necessary.

Special lecture “ The genetic complexities of human oculocutaneous albinism: a model of melanin regulation” Dr. Richard King reported the model system for the study of normal and abnormal human pigmentation in oculocutaneous albinism (OCA); he identified four major genes responsible. Mutations of the tyrosinase gene produce OCA1 or tyrosinase related OCA, and at least 100 different mutations of this gene have been identified. Mutations of the P gene are responsible for OCA2 or tyrosinase positive OCA, the most common type of OCA in humans. He analyzed P gene mutation on individuals with a phenotype compatible with OCA2. One common 2.7 kb deletion mutation has been found in African-American and African individuals. A mutation in the TRP1 gene has been found in one individual with OCA3 or brown OCA. Cultured melanocytes from this individual have no TRP1 mRNA and demonstrate a significant reduction but not a total loss of DHICA oxidase function. After his presentation there were several interesting questions. One question asked if there is a relationship between tyrosinase gene mutation and P gene mutation or not. His answer was yes and he mentioned two possible mechanisms; one possibility is that the two genes exist on very close site, and another possibility is that P gene plays an important role on the management of promoter of tyrosinase gene. One another question asked the presence of the patient with TRP2 mutation. His answer was no.

Analysis of melanin - Dr. Shosuke Ito developed microanalytical methods to qualify eumelanin (EM) and pheomelanin (PM) based on the HPLC analysis of their specific degradation products pyrrole-2,3,5-tricarboxylic acid (PTCA) and aminohydroxyphenylalanine. He showed that 1) total melanin (EM+PM) can be dissolved in hot Soluene-350, 2) EM can be dissolved in NaOH-H₂O₂ after removal of PM by heating in hydriodic acid, and 3) PM can be preferentially dissolved in NaOH. He also mentioned that to see the total melanin, spectrophotometric method using Soluene-350 is the best, and this method is available for cultured cells. He also commented that an important point is that Soluene-350 is the trade name, to check the total melanin, he uses 500 nm not 350 nm. Dr. Ozeki Hiroyuki in Dr. Ito's group presented a comparison of spectrophotometric methods (Sp. EM)/spectrophotometric method using Soluene-350 (total M). He found that the comparison of Sp. EM/total M ratio of brown eumelanin in mice hair was about a half that of black eumelanin, although the PTCA/total M ratio indicates that the proportions of DHICA-derived units were similar. He also showed that 1) Sp. EM/total M ratio correlates to the percentage content of DHICA-derived units, 2) the Sp. EM/total M ratio of DHICA melanin increases as the polymerization proceeds, and 3) the Sp. EM/total M ratio is a parameter as useful as the PTCA/total M ratio in distinguishing chemical properties of eumelanins.

Adult T cell leukemia-derived factor (ADF) / thioredoxin - Dr. Yoko Funasaka in Kobe University studied the effect of ADF/ human homologue of thioredoxin in cultured human keratinocytes. She has already reported that UVB irradiation induces the strong expression of ADF in cultured human keratinocytes. To study the effect of ADF on UVB-induced melanogenesis, she analyzed the MSH receptor binding activity using ¹²⁵I labeled MSH, the expression of MSH receptor mRNA using the melanocortin 1 receptor (MC1-R) cDNA and ³H-thymidine uptake in normal human melanocytes. She showed that ADF increased MSH receptor binding activity of MSH and MC1-R mRNA expression. ADF has not stimulated DNA synthesis neither alone nor with endothelin-1, stem cell factor, hepatocyte growth

factor, and basic fibroblast growth factor, but ADF increased MSH-induced DNA synthesis. These results indicate that ADF is one of the stimulatory factors for UVB induced melanogenesis via upregulating MSH receptor binding activity with increasing MC1-R mRNA expression and increasing the DNA synthesis by MSH stimulation. After her presentation, there was a question which asked the mechanism of increasing of MSH binding activity, so that, increasing the number of MSH receptor or increasing the affinity of them. Her answer was the mechanism is still not clear.

Tyrosinase related proteins - The enzymatic functions of tyrosinase, TRP1 and TRP2 are already becoming clear. TRP1 can oxidize DHICA produced by TRP2. However the effect of those enzymes on each other is still not clear. Dr. Kobayashi studied the stabilizing function of the b-locus protein on tyrosinase. He investigated the effect of mutations at the brown locus on stability of tyrosinase in cells. Pulse labeling and chase experiments showed that tyrosinase degraded more quickly in melan-b melanocytes, homozygous for the brown mutation than in melan-a melanocytes, the wild type. Less stability of tyrosinase in melan-b cells was partly rescued by transfection of the wild-type TRP1 gene along with phenotypic rescues. His results clearly showed that TRP1 could stabilize tyrosinase in melanocytes and might also contribute to the polymerization of DHI into melanin.

Melanogenic inhibitor - Dr. Yokota and Dr. Kameyama reported the new melanogenic inhibitor, ascorbic acid 2-phosphate sodium salt (APS). They reported that APS is an ascorbic acid derivative that is stable in aqueous solution unlike ascorbic acid. 8×10^{-3} M APS decreased the total amount of melanin approximately 30% , and suppressed ^{14}C -thiouracil uptake approximately 50% without suppression of ^3H -thymidine uptake in cultured B16 melanoma cells. Relatively high concentration of APS (2.7×10^{-2} M) suppressed the activities of tyrosinase, TRP1 and TRP2 significantly on cultured melan-a cells. Then 3% APS cream was applied to the patients with hyperpigmented disorders such as melasma. The results showed that APS cream was effective on 9 out of 20 patients. These findings clearly indicated that APS application can be useful for some patients with hyperpigmented diseases. After their presentation there was a question which ask the absorption of APS. Dr. Kameyama answered although they don't have the experimental data of APS, similar ascorbic acid derivative magnesium L-ascorbyl-2-phosphate showed that approximately 2% was absorbed into epidermis or dermis on diffusion cell chamber assay.

Bibliography :

The Bibliography published in this issue covers the period November, 1995 through January, 1996. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. We have attempted to highlight any publications which include a member of the PASPCR with a star.

MELANINS, MELANOGENS & MELANOGENESIS

- Barker D, Dixon K, Medrano EE, Smalara D, Im S, Mitchell D, Babcock G, Abdel-Malek ZA: Comparison of the responses of human melanocytes with different melanin contents to ultraviolet B irradiation. *Cancer Res* 55:4041-4046 (1995).
- Armstrong SG, Dean RT: A sensitive fluorometric assay for protein-bound DOPA and related products of radical-mediated protein oxidation. *Redox Rep* 1:291-298 (1995). 3131.
- Bechthomsen N, Wulf HC: Carcinogenic and melanogenic effects of a filtered metal halide UVA source and a tubular fluorescent UVA tanning source with or without additional solar-simulated UV radiation in hairless mice. *Photochem Photobiol* 62:773-779 (1995). 2887.
- Benedito E, Jimenezcervantes C, Cubillana JD, Solano F, Lozano JA, Garciaborron JC: Biochemical characterization of the melanogenic system in the eye of adult rodents. *Bba-Protein Struct Mol Enzym* 1252:217-224 (1995). 2883.
- Benromdhane K, Khattech R, Benothman M, Gamoudi A, Ammar A, Cammoun M: Melanin production in medullary thyroid carcinoma. *Histopathology* 27:569-571 (1995). 3310.
- Bilgihan A, Bilgihan MK, Akata RF, Aricioglu A, Hasanreisoglu B: Antioxidative role of ocular melanin pigment in the model of lens induced uveitis. *Free Radical Biol Med* 19:883-885 (1995). 2932.
- Constantinescu CS: Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: A rationale for light therapy in multiple sclerosis. *Med Hypotheses* 45:455-458 (1995). 3225.

- Cumming P, Ase A, Diksic M, Harrison J, Jolly D, Kuwabara H, Laliberte C, Gjedde A: Metabolism and blood-brain clearance of L-3,4-dihydroxy-[H-3]phenylalanine ([H-3]DOPA) and 6-[F-18]fluoro-L-DOPA in the rat. *Biochem Pharmacol* 50:943-946 (1995). 2879.
- Dacquisto F, Carnuccio R, Dischia M, Misuraca G: 5,6-dihydroxyindole-2-carboxylic acid, a diffusible melanin precursor, is a potent stimulator of lipopolysaccharide-induced production of nitric oxide by J774 macrophages. *Life Sci* 57:PL401-PL406 (1995). 3178.
- Diffey BL, Healy E, Thody AJ, Rees JL: Melanin, melanocytes, and melanoma. *Lancet* 346:1713(1995). 3321.
- Dunford R, Land EJ, Rozanowska M, Sarna T, Truscott TG: Interaction of melanin with carbon- and oxygen-centered radicals from methanol and ethanol. *Free Radical Biol Med* 19:735-740 (1995). 2931.
- Englaro W, Rezzonico R, Durandclement M, Lallemand D, Ortonne JP, Ballotti R: Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. *J Biol Chem* 270:24315-24320 (1995). 2830.
- Facchini PJ, Deluca V: Phloem-specific expression of tyrosine dopa decarboxylase genes and the biosynthesis of isoquinoline alkaloids in opium poppy. *Plant Cell* 7:1811-1821 (1995). 3182.
- Foss AJE: Immunohistochemical staining followed by bleaching of melanin: A practical method for ophthalmic pathology - Reply. *Brit J Biomed Sci* 52:326(1995). 3324.
- Gilhar A, Gershonibaruch R, Margolis A, Benderly A, Brandes JM: Dopa reaction of fetal melanocytes before and after skin transplantation on to nude mice. *Br J Dermatol* 133:884-889(1995). 3313.
- Hunt G, Thody AJ: Agouti protein can act independently of melanocyte-stimulating hormone to inhibit melanogenesis. *J Endocrinol* 147:R1-R4 (1995). 2942.
- Ischiropoulos H, Duran D, Horwitz J: Peroxynitrite-mediated inhibition of DOPA synthesis in PC12 cells. *J Neurochem* 65:2366-2372 (1995). 2921.
- Isiklar I, Leeds NE, Fuller GN, Kumar AJ: Intracranial metastatic melanoma: Correlation between MR imaging characteristics and melanin content. *Am J Roentgenol* 165:1503-1512 (1995). 3135.
- Jacobson ES, Hove E, Emery HS: Antioxidant function of melanin in black fungi. *Infect Immun* 63:4944-4945 (1995). 3156.
- Jastrzebska MM, Isotalo H, Paloheimo J, Stubb H: Electrical conductivity of synthetic DOPA-melanin polymer for different hydration states and temperatures. *J Biomater Sci-Polym Ed* 7:577-586 (1995). 3327.
- Jimbow M, Marusyk H, Jimbow K: The *in vivo* melanocytotoxicity and depigmenting potency of N-2,4-acetoxypheyl thioethyl acetamide in the skin and hair. *Br J Dermatol* 133:526-536 (1995). 2839.
- Kawai K, Ohta H, Channing MA, Kubodera A, Eckelman WC: Synthesis of polymer-bound 6-mercuric carboxylate DOPA precursors and solid phase labelling method of 6- radioiodinated L-DOPA. *Appl Radiat Isotopes* 47:37-44 (1996). 3388.
- Kingsolver JG: Viability selection on seasonally polyphenic traits: Wing melanin pattern in western white butterflies. *Evolution* 49:932-941 (1995). 3013.
- Kivela T: Immunohistochemical staining followed by bleaching of melanin: A practical method for ophthalmic pathology. *Brit J Biomed Sci* 52:325-326 (1995). 3323.
- Lee CH, Koshino H, Chung MC, Lee HJ, Kho YH: MR304A, a new melanin synthesis inhibitor produced by *Trichoderma harzianum*. *J Antibiot* 48:1168-1170 (1995). 2955.
- Maurer J, Knollmann FD, Schlums D, Garbe C, Vogl TJ, Bier J, Felix R: Role of high-resolution magnetic resonance imaging for differentiating melanin-containing skin tumors. *Invest Radiol* 30:638-643 (1995). 3103.
- Meyer AJ, Nahass GT: Hyperpigmented patches on the dorsa of the feet. *Arch Dermatol* 131:1447-1448 (1995). 3264.
- Moore PS, Dominici P, Voltattorni CB: Transaldimination induces coenzyme reorientation in pig kidney Dopa decarboxylase. *Biochimie* 77:724-728 (1995). 3303.
- Nakagawa S, Kato T, Kumasaka N, Tagami H: Malignant blue nevus: Improved demonstration of cellular atypicality after bleaching of melanin. *European J Dermatology* 5:575-577 (1995). 2996.
- Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou BK, Silvers WK, Mintz B: Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. *Proc Natl Acad Sci USA* 92:10152-10156 (1995). 2918.
- Radwanska A, Frackowiak T, Ibrahim H, Aubry AF, Kaliszan R: Chromatographic modelling of interactions between melanin and phenothiazine and dibenzazepine drugs. *Biomed Chromatogr* 9:233-237 (1995). 3089.
- Rapaport DH, Rakic P, Yasamura D, Lavail MM: Genesis of the retinal pigment epithelium in the macaque monkey. *J Comp Neurol* 363:359-376 (1995). 3394.
- Rosei MA, Mosca L: Production of melanin pigments by chemical and enzymatic oxidation of tetrahydroisoquinolines. *Biochem Mol Biol Int* 35:1253-1259 (1995). 2925.
- Sakakibara Y, Takami Y, Zwieb C, Nakayama T, Suiko M, Nakajima H, Liu MC: Purification, characterization, and molecular cloning of a novel rat liver Dopa/tyrosine sulfotransferase. *J Biol Chem* 270:30470-30478 (1995). 3304.
- Sanblas G, Guanipa O, Moreno B, Pekerar S, Sanblas F: *Cladosporium carrionii* and *Hormoconis resinae* (C-resinae): Cell wall and melanin studies. *Curr Microbiol* 32:11-16 (1996). 3283.
- Schraermeyer U: Transport of endocytosed material into melanin granules in cultured choroidal melanocytes of cattle - New insights into the relationship of melanosomes with lysosomes. *Pigm Cell Res* 8:209-214 (1995). 3259.
- Smith SB, Bora N, Mccool D, Kutty G, Wong P, Kutty RK, Wiggert B: Photoreceptor cells in the vitiligo mouse die by apoptosis -TRPM-2/clusterin expression is increased in the neural retina and in the retinal pigment epithelium. *Invest Ophthalmol Visual Sci* 36:2193-2201 (1995). 2797.

- ¶Sugumaran M, Nellaiappan K, Scott T, Amaratunga C: Complex formation between mushroom tyrosinase and manduca dopachrome isomerase. *Pigm Cell Res* 8:180-186 (1995). 3255.
- Takano Y, Kubo Y, Shimizu K, Mise K, Okuno T, Furusawa I: Structural analysis of PKS1, a polyketide synthase gene involved in melanin biosynthesis in *Colletotrichum lagenarium*. *Mol Gen Genet* 249:162-167 (1995). 3163.
- Talve LAI, Collan YUI, Alanen KA: Bleaching of melanin before image cytometry of the DNA content of pigmented skin tumors. *Anal Quant Cytol Histol* 17:344-350 (1995). 2833.
- Vanderheijden A, Vandijk JE, Lemmens AG, Beynen AC: Spleen pigmentation in young C57BL mice is caused by accumulation of melanin. *Lab Anim* 29:459-463 (1995). 2923.
- Waite JH: Precursors of quinone tanning: Dopa-containing proteins. *Redox-Active Amino Acids in B* 258:1-20 (1995). 2969.

MELANOCYTES & KERATINOCYTES

- Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G: Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. *J Immunol* 156:208-217 (1996). 3335.
- Baran R, Perrin C: Pseudofibrokeratoma of the nail apparatus with melanocytic pigmentation (vol 74, pg 449, 1994). *Acta Derm Venereol [Stockh]* 75:414(1995). 3092.
- Barnhill RL, Fleischli M: Histologic features of congenital melanocytic nevi in infants 1 year of age or younger. *J Am Acad Dermatol* 33:780-785 (1995). 3047.
- Boersma BR, Westerhof W, Bos JD: Repigmentation in vitiligo vulgaris by autologous minigrafting: Results in nineteen patients. *J Am Acad Dermatol* 33:990-995 (1995). 3202.
- ¶Chakraborty A, Slominski A, Ermak G, Hwang J, Pawelek J: Ultraviolet B and melanocyte-stimulating hormone (MSH) stimulate mRNA production for α MSH receptors and proopiomelanocortin-derived peptides in mouse melanoma cells and transformed keratinocytes. *J Invest Dermatol* 105:655-659 (1995). 3065.
- Clark WH, Tucker MA, Goldstein AM: Parenchymal-stromal interactions in neoplasia - Theoretical considerations and observations in melanocytic neoplasia. *Acta Oncol* 34:749-757 (1995). 2848.
- Duvic M: The minigrafting test for vitiligo: Detection of stable lesions for melanocyte transplantation - Reply. *J Am Acad Dermatol* 33:1061(1995). 3207.
- Falabella R: The minigrafting test for vitiligo: Detection of stable lesions for melanocyte transplantation - Reply. *J Am Acad Dermatol* 33:1061-1062 (1995). 3206.
- Gilhar A, Zelickson B, Ulman Y, Etzioni A: *In vivo* destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. *J Invest Dermatol* 105:683-686 (1995). 3066.
- ¶Gomez LA, Rieber MS, Rieber M: Decrease in actin gene expression in melanoma cells compared to melanocytes is partly counteracted by BrdU- induced cell adhesion and antagonized by L-tyrosine induction of terminal differentiation. *Biochem Biophys Res Commun* 216:84-89 (1995). 3082.
- Gonzalez JG, Ortega VV, Redondo M, Vicente JR: Comparative study of experimental ocular melanoma using two implantation techniques of B16-F10 melanocytes. *Pigm Cell Res* 8:173-179 (1995). 3254.
- Hara M, Yaar M, Gilchrist BA: Endothelin-1 of keratinocyte origin is a mediator of melanocyte dendricity. *J Invest Dermatol* 105:744-748 (1995). 3143.
- Harbour JW, Augsburg JJ, Eagle RC: Initial management and followup of melanocytic iris tumors. *Ophthalmology* 102:1987-1993 (1995). 3361.
- ¶Hunt G, Kyne S, Ito S, Wakamatsu K, Todd C, Thody AJ: Eumelanin and phaeomelanin contents of human epidermis and cultured melanocytes. *Pigm Cell Res* 8:202-208 (1995). 3258.
- Kharkevich GY, Kazubskaya TP, Agapova RK, Musatov VK, Trubnikov VI, Demidov LV, Garkavtseva RF: Clinical genetic aspects of cutaneous malignant melanoma .2. Interrelation and pathogenetic commonality with dysplastic nevus syndrome. *Genetika* 31:1562-1565 (1995). 3386.
- Klaver CCW, Hoyng CB, Dejong PTVM: Pigmentary irregularities and optic disc edema after heart transplantation. *Arch Ophthalmol* 113:1281-1285 (1995). 2782.
- Liu PY, Lontz W, Bondesson L, Johansson O: The possible role of α , β - and γ 3-melanocyte stimulating hormone-containing keratinocytes in the initiation of vitiligo vulgaris. *European J Dermatology* 5:625-630 (1995). 2999.
- Maeurer MJ, Martin DM, Storkus WJ, Lotze MT: TCR usage in CTLs recognizing melanoma melanocyte antigens. *Immunol Today* 16:603-604 (1995). 3230.
- ¶Mortarini R, Gismondi A, Maggioni A, Santoni A, Herlyn M, Anichini A: Mitogenic activity of laminin on human melanoma and melanocytes: Different signal requirements and role of β 1 integrins. *Cancer Res* 55:4702-4710 (1995). 2796.
- Oka M, Ogita K, Ando H, Kikkawa U, Ichihashi M: Differential down-regulation of protein kinase C subspecies in normal human melanocytes: Possible involvement of the zeta subspecies in growth regulation. *J Invest Dermatol* 105:567-571 (1995). 2798.
- Okumoto H, Nishioka M, Miura I, Obika M: Melanosome formation in cultured amelanotic melanophores of *Rana brevipoda* by a frog tyrosinase cDNA transfection. *Pigm Cell Res* 8:187-193 (1995). 3256.
- Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM, Christophers E: Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. *Am J Pathol* 147:1615-1625 (1995). 3253.
- Rupnik M, Zorec R: Intracellular Cl⁻ modulates Ca²⁺-induced exocytosis from rat melanotrophs through GTP binding proteins. *Pflugers Arch-Eur J Physiol* 431:76-83 (1995). 3180.

- Scott GA, Liang H, Cassidy LL: Developmental regulation of focal contact protein expression in human melanocytes. *Pigm Cell Res* 8:221-228 (1995). 3260.
- Seregard S, Aftrampe E, Manssonbrahme E, Kock E, Bergenmar M, Ringborg U: Prevalence of primary acquired melanosis and nevi of the conjunctiva and uvea in the dysplastic nevus syndrome: A case-control study. *Ophthalmology* 102:1524-1529 (1995). 2846.
- Skenderkalnenas TM, English DR, Heenan PJ: Benign melanocytic lesions: Risk markers or precursors of cutaneous melanoma? *J Am Acad Dermatol* 33:1000-1007 (1995). 3203.
- Takahashi H, Saitoh K, Kishi H, Parsons PG: Immunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumours. *Virchows Archiv* 427:283-288 (1995). 3134.
- Thody AJ: Epidermal melanocytes: Their regulation and role in skin pigmentation. *European J Dermatology* 5:558-565 (1995). 2995.
- Thomson JAF: The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells (vol 11, pg 691, 1995). *Oncogene* 11:2457(1995). 3312.
- Westerhof W, Boersma BA: The minigrafting test for vitiligo: Detection of stable lesions for melanocyte transplantation. *J Am Acad Dermatol* 33:1061(1995). 3205.
- Zumgottesberge AMM: Calcium dependent intercellular interaction of the neural crest derivate-melanocytes and the epithelial cells of the vestibular organ. *Acta Oto-Laryngol* 360-361 (1995). 3262.

MELANOMA & METASTASIS

- Adler V, Fuchs SY, Kim J, Kraft A, King MP, Pelling J, Ronai Z: jun-NH2-terminal kinase activation mediated by UV-induced DNA lesions in melanoma and fibroblast cells. *Cell Growth Differ* 6:1437-1446 (1995). 3074.
- Aitchison TC, Sirel JM, Watt DC, Mackie RM: Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. *Br Med J* 311:1536-1539 (1995). 3267.
- Akslen LA: Melanoma and sun exposure. *Lancet* 346:1225(1995). 2941.
- Anasagasti MJ, Avivi C, Vidalvanaclocha F: Interleukin-1 (IL-1) activation of hydrogen peroxide production by liver sinusoidal endothelial cells induces the *in vitro* lysis of B16 melanoma cells. *Cells of the Hepatic Sinusoid* 204-206 (1995). 3123.
- ¶ Ariyan S, Poo WJ, Bolognia J, Buzaid A, Ariyan T: Multiple primary melanomas: Data and significance. *Plast Reconstr Surg* 96:1384-1389 (1995). 3054.
- Azizi E, Friedman J, Pavlotsky F, Iscovich J, Bornstein A, Shafir R, Trau H, Brenner H, Nass D: Familial cutaneous malignant melanoma and tumors of the nervous system: A hereditary cancer syndrome. *Cancer* 76:1571-1578 (1995). 2895.
- ¶ Baer SC, Schultz D, Synnestvedt M, Elder DE: Desmoplasia and neurotropism: Prognostic variables in patients with stage I melanoma. *Cancer* 76:2242-2247 (1995). 2984.
- Bajetta E, Buzzoni R, Vicario G: Combined carboplatin and cytosine arabinoside in metastatic melanoma refractory to dacarbazine. *Tumori* 81:238-240 (1995). 2906.
- Bakker ABH, Marland G, Deboer AJ, Huijbens RJF, Danen EHJ, Adema GJ, Figdor CG: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells *in vitro*. *Cancer Res* 55:5330-5334 (1995). 3058.
- Barnhill RL, Flotte TJ, Fleischli M, Perezatayde A: Cutaneous melanoma and atypical spitz tumors in childhood. *Cancer* 76:1833-1845 (1995). 3057.
- Bedikian AY, Weiss GR, Legha SS, Burris HA, Eckardt JR, Jenkins J, Eton O, Buzaid AC, Smetzer L, Vonhoff DD, Benjamin RS: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. *J Clin Oncol* 13:2895-2899 (1995). 3269.
- Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL: Screening for cutaneous melanoma by skin self-examination. *J Nat Cancer Inst* 88:17-23 (1996). 3331.
- Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G: Positron emission tomography and ultrasonography - A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. *Arch Dermatol* 131:1394-1398 (1995). 3263.
- Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, Lahaye T, Degiovanni G, Deraemaeker R, Beauduin M, Sastre X, Salamon E, Dreno B, Jager E, Knuth A, Chevreau C, Suci S, Lachapelle JM, Pouillart P, Parmiani G, Lejeune F, Cerottini JC, Boon T, Marchand M: Expression of MAGE genes in primary and metastatic cutaneous melanoma. *Int J Cancer* 63:375-380 (1995). 2951.
- Cao XT, Zhang WP, Gu S, Yu YZ, Tao Q, Ye TX: Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene transfected melanoma cells combined with low-dose interleukin-2. *J Cancer Res Clin Oncol* 121:721-728 (1995). 3222.
- Christophers E, Hauschild A: Malignant melanoma in adolescence. *Dtsch Med Wochenschr* 120:1452(1995). 2890.
- Cirielli C, Riccioni T, Yang CL, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC: Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis *in vitro* and *in vivo*. *Int J Cancer* 63:673-679 (1995). 3219.
- Cohen LM: Lentigo maligna and lentigo maligna melanoma. *J Am Acad Dermatol* 33:923-936 (1995). 3201.

- Coppock DL, Buffolino P, Kopman C, Nathanson L: Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity. *Exp Cell Res* 221:92-102 (1995). 2934.
- Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM, Kugler J, Rodrigue LJ: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. *J Clin Oncol* 13:2776-2783 (1995). 3048.
- ¶Desai DS, Niles RM: Expression and regulation of retinoid X receptors in B16 melanoma cells. *J Cell Physiol* 165:349-357 (1995). 2938.
- ¶Devries TJ, Kitson JL, Silvers WK, Mintz B: Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. *Cancer Res* 55:4681-4687 (1995). 2795.
- Dewaardsiebinga I, Kool J, Jager MJ: HLA antigen expression on uveal melanoma cells *in vivo* and *in vitro*. *Hum Immunol* 44:111-117 (1995). 2802.
- Dooley TP, Mattern VL, Moore CM, Robinson ES: UV-induced melanoma - A karyotype with a single translocation is stable after allografting and metastasis. *Cancer Genet Cytogenet* 83:155-159 (1995). 2807.
- Elibol O, Yuksel N, Egilmez HR, Arici S, Mizrak B: A case of primary orbital melanoma treated by local excision. *Br J Ophthalmol* 79:1146-1148 (1995). 3318.
- Elwood JM: Skin self-examination and melanoma. *J Nat Cancer Inst* 88:3-5 (1996). 3330.
- Engelhard V: Hot Paper - Tumor Immunology - Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T- Cell Lines - by Cox,A.L., Skipper,J., Chen,Y., Henderson,R.A., Engelhard,V.H., Hunt,D.F., Slingluff,D.F. *Scientist* 9:15(1995). 2964.
- Evans RA: Malignant melanoma: Primary surgical management (excision and node dissection) based upon pathology and staging. *Cancer* 76:2384-2385 (1995). 2985.
- Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY: Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. *Cancer Res* 55:4988-4994 (1995). 2946.
- Garkavtseva RF, Sitnikova TS, Kazubskaya TP, Demidov LV, Kharkevich GY: Clinical genetic aspects of cutaneous malignant melanoma .1. Incidence, familial study, genetic heterogeneity. *Genetika* 31:1557-1561 (1995). 3385.
- Gharib M, Tamboise E, Tamboise A, Lievre N, Verola O, Beaupain R: Effects of lymphokine activated killer cells on melanoma nodules maintained in three-dimensional culture. *Int J Oncol* 7:1327-1332 (1995). 3221.
- Ghazvini S, Kroll S, Char DH, Frigillana H: Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma. *Invest Ophthalmol Visual Sci* 36:2762-2767 (1995). 3275.
- Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, Fountain JW: Homozygous loss of the p15(INK4B) gene (and not the p16(INK4) gene) during tumor progression in a sporadic melanoma patient. *Cancer Res* 55:5531-5535 (1995). 2987.
- Grange F, Chompret A, Guilloudbataille M, Guillaume JC, Margulis A, Prade M, Demenais F, Avril MF: Comparison between familial and nonfamilial melanoma in France. *Arch Dermatol* 131:1154-1159 (1995). 2837.
- ¶Gruber JR, Desai S, Blusztajn JK, Niles RM: Retinoic acid specifically increases nuclear PKC α and stimulates AP-1 transcriptional activity in B16 mouse melanoma cells. *Exp Cell Res* 221:377-384 (1995). 3190.
- Guarini A, Gansbacher B, Cronin K, Fierro MT, Foa R: IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. *Cytokines Mol Ther* 1:57-64 (1995). 3151.
- Guo HB, Stoffelwagner B, Bierwirth T, Mezger J, Klingmuller D: Clinical significance of serum S100 in metastatic malignant melanoma (vol 31A, pg 924, 1995). *Eur J Cancer* 31A:1898-1902 (1995). 2994.
- Gupta R, Aggarwal R, Puri AS, Shukla S, Pandey R, Naik SR: Endoscopic appearance of malignant melanoma metastatic to the upper gastrointestinal tract. *Endoscopy* 27:631(1995). 2975.
- Harris MN: Malignant melanoma: Primary surgical management (excision and node dissection) based upon pathology and staging - Reply. *Cancer* 76:2385(1995). 2986.
- Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Kim DK, Dasgupta TK: β (1) integrin expression in malignant melanoma predicts occult lymph node metastases. *Surgery* 118:669-675 (1995). 2790.
- Hill RA, Reddi S, Kenney ME, Ryan J, Liaw LH, Garrett J, Shirk J, Cheng GZ, Krasieva T, Berns MW: Photodynamic therapy of ocular melanoma with bis silicon 2,3-naphthalocyanine in a rabbit model. *Invest Ophthalmol Visual Sci* 36:2476-2481 (1995). 3063.
- Holland EA, Beaton SC, Becker TM, Gullet OMC, Peters BA, Rizos H, Kefford RF, Mann GJ: Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. *Oncogene* 11:2289-2294 (1995). 3311.
- Holly EA, Aston DA, Ahn DK, Smith AH: Intraocular melanoma linked to occupations and chemical exposures. *Epidemiology* 7:55-61 (1996). 3319.
- Hu LK, Hasan T, Gragoudas ES, Young LHY: Photoimmunotherapy of human uveal melanoma cells. *Exp Eye Res* 61:385-391 (1995). 2855.
- Husain S, Gordon KK, Spitz J, Sultan M, Silvers DN: Melanoma *in situ* of the sole that extended into a skin graft: Reflections on the biology of melanoma. *Arch Dermatol* 131:1468-1469 (1995). 3265.
- Imro MA, Castagneto C, Bosco O, Modena P, Lanza L, Puppo F, Filaci G, Indiveri F, Scudeletti M: CD4+ Th0 cell clones, isolated from a metastatic lymph node of a melanoma patient, possess cytolytic function. *Cancer Immunol Immunother* 41:210-216 (1995). 3227.

- Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW: Phase II trial of interleukin 1 α and indomethacin in treatment of metastatic melanoma. *J Nat Cancer Inst* 88:44-49 (1996). 3332.
- Jean D, Hermann J, Rodrigueslima F, Barel M, Balbo M, Frade R: Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: Amino-acid-sequence identities with procathepsin L. *Biochem J* 312:961-969 (1995). 3353.
- Jonescaballere M, Penas PF, Buezo GF, Fraga J, Aragues M: Malignant melanoma appearing in a seborrheic keratosis. *Br J Dermatol* 133:1016-1018 (1995). 3316.
- Kanitakis J, Montazeri A, Ghohestani R, Faure M, Claudy A: Bcl-2 oncoprotein expression in benign nevi and malignant melanomas of the skin. *European J Dermatology* 5:501-507 (1995). 2853.
- Katz NR, Finger PT, McCormick SA, Tello C, Ritch R, Sirota M, Kranz O: Ultrasound biomicroscopy in the management of malignant melanoma of the iris. *Arch Ophthalmol* 113:1462-1463 (1995). 3096.
- Kauranen M, Kiviniitty K, Weckstrom M: Voltage-activated and spontaneous Cl⁻-channel activity in cultured human melanoma cell-line A2058. *Bba-Mol Cell Res* 1269:281-289 (1995). 3183.
- Komori H, Ito M: Conversion of short-chain ceramides to short-chain ceramide GM3 in B16 melanoma cells. *FEBS Lett* 374:299-302 (1995). 3040.
- ♀Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D: Expression of cytokine mRNA in human melanoma tissues. *Cancer Immunol Immunother* 41:151-156 (1995). 2801.
- Lawrence W: The association between melanoma, lymphoma, and other primary neoplasms - Invited commentary. *Arch Surg* 130:1061(1995). 2784.
- Ledrean E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F: HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4(+) melanoma-infiltrating lymphocytes. *Eur J Immunol* 25:2732-2736 (1995). 2907.
- Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulos NEJ: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. *Cancer* 77:89-96 (1996). 3365.
- Levkut M, Kolodzieyski L, Ledecy V, Daxnerova K: Familial melanoma in the progeny of a Duroc and Slovak White crossbred sow. *J Comp Pathol* 113:233-239 (1995). 2777.
- Lindholm P, Leskinen S, Nagren K, Lehtikoinen P, Ruotsalainen U, Teras M, Joensuu H: Carbon-11-methionine PET imaging of malignant melanoma. *J Nucl Med* 36:1806-1810 (1995). 2844.
- Lingam MK, McKay AJ: Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma. *Br J Surg* 82:1346-1348 (1995). 2786.
- Lingam MK, McKay AJ, Mackie RM, Aitchison T: Single-centre prospective study of isolated limb perfusion with melphalan in the treatment of subungual malignant melanoma. *Br J Surg* 82:1343-1345 (1995). 2785.
- Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, Seymour LW: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. *Biochem Biophys Res Commun* 217:721-727 (1995). 3351.
- ♀Liu B, Khan WA, Hannun YA, Timar J, Taylor JD, Lundy S, Butovich I, Honn KV: 12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C- α in melanoma cells: Role of receptor-mediated hydrolysis of inositol phospholipids (vol 92, pg 9323, 1995)(Correction). *Proc Natl Acad Sci USA* 92:11322(1995). 3025.
- Logani S, Cho AS, Ali BH, Withers HR, McBride WH, Kozlov KL, Hall MO, Lee DA, Straatsma BR: Single-dose compared with fractionated-dose radiation of the OM431 choroidal melanoma cell line. *Am J Ophthalmol* 120:506-510 (1995). 2781.
- Mahaney FX: Nocturnal animals help shed light on human melanoma. *J Nat Cancer Inst* 87:1584-1585 (1995). 2859.
- Malitschek B, Fornzler D, Scharlt M: Melanoma formation in *Xiphophorus*: A model system for the role of receptor tyrosine kinases in tumorigenesis. *Bioessays* 17:1017-1023 (1995). 3289.
- Mars U, Larsson BS: New thioureas and related substances intended for melanoma targeting. *Pigm Cell Res* 8:194-201 (1995). 3257.
- Melani C, Sulesuso J, Arienti F, Maccalli C, Passerini F, Colombo MP, Parmiani G: A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. *Hum Gene Ther* 6:1427-1436 (1995). 3112.
- ♀Meyskens FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK: Randomized trial of adjuvant human interferon- γ versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group Study. *J Nat Cancer Inst* 87:1710-1713 (1995). 3068.
- Missol E, Sochanik A, Szala S: Introduction of murine Il-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. *Cancer Lett* 97:189-193 (1995). 3217.
- Mooy CM, Luyten GPM, Dejong PTVM, Jensen OA, Luider TM, Vanderham F, Bosman FT: Neural cell adhesion molecule distribution in primary and metastatic uveal melanoma. *Hum Pathol* 26:1185-1190 (1995). 3088.
- Mooy CM, Luyten GPM, Dejong PTVM, Luider TM, Stijnen T, Vandeham F, Vanvroomhoven CCJ, Bosman FT: Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. *Am J Pathol* 147:1097-1104 (1995). 2775.
- Muller C, Lepape A, Musset M, Baulieu JL, Delarue A, Binz H, Vaillant L, Lorette G: Scintigraphy with Technetium-99m-J001X acylated polygalactoside in melanoma recurrence. *European J Dermatology* 5:600-606 (1995). 2998.

- Muthukkumar S, Nair P, Sells SF, Maddiwar NG, Jacob RJ, Rangnekar VM: Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. *Mol Cell Biol* 15:6262-6272 (1995). 2915.
- Nannmark U, Johansson BR, Bryant JL, Unger ML, Hokland ME, Goldfarb RH, Basse PH: Microvessel origin and distribution in pulmonary metastases of B16 melanoma: Implication for adoptive immunotherapy. *Cancer Res* 55:4627-4632 (1995). 2793.
- Nathan FE, Mastrangelo MJ: Adjuvant therapy for cutaneous melanoma. *Semin Oncol* 22:647-661 (1995). 3375.
- Nelemans PJ, Rampen FHJ, Ruiten DJ, Verbeek ALM: An addition to the controversy on sunlight exposure and melanoma risk: A meta-analytical approach. *J Clin Epidemiol* 48:1331-1342 (1995). 3208.
- Nip J, Brodt P: The role of the integrin vitronectin receptor, $\alpha(v)\beta(3)$ in melanoma metastasis. *Cancer Metastasis Rev* 14:241-252 (1995). 2897.
- O'Brien CJ, Uren RF, Thompson JF, Howmangiles RB, Petersenschaefter K, Shaw HM, Quinn MJ, McCarthy WH: Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. *Am J Surg* 170:461-466 (1995). 3045.
- Ota T, Muto M, Nakano J, Hamanaka S, Irie R, Asagami C: Immunohistological reaction mechanism of anti-monosialoganglioside monoclonal antibody, MAb 202, showing predominant cytotoxicity for malignant melanoma. *Tohoku J Exp Med* 177:1-12 (1995). 3226.
- Pearlman NW, Robinson WA, Dreiling LK, McIntyre RC, Gonzales R: Modified ilioinguinal node dissection for metastatic melanoma. *Am J Surg* 170:647-650 (1995). 3197.
- Peris K, Keller G, Chimenti S, Amantea A, Kerl H, Hofler H: Microsatellite instability and loss of heterozygosity in melanoma. *J Invest Dermatol* 105:625-628 (1995). 2799.
- Pijpers R, Collet GJ, Meijer S, Hoekstra OS: The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. *Eur J Nucl Med* 22:1238-1241 (1995). 2976.
- Platz A, Jungnelius U, Grafstrom E, Lagerlof B, Mannervik B, Ringborg U: Glutathione transferase p1-1 expression in human melanoma metastases: Correlation to N-RAS mutations and expression. *Acta Oncol* 34:759-765 (1995). 2849.
- Poremba C, Yandell DW, Metze D, Kamanabrou D, Bocker W, Dockhorndworniczak B: Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. *Oncol Res* 7:331-339 (1995). 3003.
- Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L: Combined vaccination with major histocompatibility Class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. *Cancer Res* 55:4941-4949 (1995). 2944.
- Retsas S: Strategies for improving survival in malignant melanoma: Focus on vindesine. *J Drug Dev Clin Practice* 7:159-171 (1995). 2880.
- Rieber MS, Rieber M: Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation. *Biochem Biophys Res Commun* 216:422-427 (1995). 3083.
- Riou JP, Ariyan S, Brandow KR, Fielding LP: The association between melanoma, lymphoma, and other primary neoplasms. *Arch Surg* 130:1056-1061 (1995). 2783.
- Robert C, Dubertret L: Ultraviolet irradiation and skin cancer. *Presse Med* 24:1610-1616 (1995). 2981.
- Rogner UC, Wilke K, Steck E, Korn B, Poustka A: The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. *Genomics* 29:725-731 (1995). 2868.
- Ruan ST, Raj BKM, Furukawa K, Lloyd KO: Analysis of melanoma cells stably transfected with $\beta(1)$, 4GalNAc transferase (G(M2)/G(D2) synthase) cDNA: Relative glycosyltransferase levels play a dominant role in determining ganglioside expression. *Arch Biochem Biophys* 323:11-18 (1995). 2882.
- Saenzsantamaria MC, McNutt NS, Shea CR: Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. *Br J Dermatol* 133:890-895 (1995). 3314.
- Saia G: Polymyositis, dermatomyositis and malignant melanoma. *Br J Dermatol* 133:1012(1995). 3315.
- Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated *in vitro* with synthetic peptides. *Cancer Res* 55:4972-4979 (1995). 2945.
- Schadendorf D, Makki A, Stahr C, Vandyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM: Membrane transport proteins associated with drug resistance expressed in human melanoma. *Am J Pathol* 147:1545-1552 (1995). 3252.
- Shuster S: Melanoma and sun exposure. *Lancet* 346:1224(1995). 2939.
- Slavik M, Liu PY, Kraut EH, Natale RB, Flaherty LE, Sondak VK: Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma - A southwest oncology group study. *Invest New Drugs* 13:143-147 (1995). 3175.
- Smit NPM, Pavel S: Induction of cytotoxicity in melanoma cells through inhibition of catechol-O-methyltransferase. *Biochem Pharmacol* 50:1955-1962 (1995). 3399.
- Smolle J, Hofmannwellenhof R, Kofler R, Cerroni L, Haas J, Kerl H: Computer simulations of histologic patterns in melanoma using a cellular automaton provide correlations with prognosis. *J Invest Dermatol* 105:797-801 (1995). 3145.
- Streetly A, Markowe H: Changing trends in the epidemiology of malignant melanoma: Gender differences and their implications for public health. *Int J Epidemiol* 24:897-907 (1995). 3046.
- Sulesuso J, Arienti F, Melani C, Colombo MP, Parmiani G: A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. *Eur J Immunol* 25:2737-2742 (1995). 2908.

- Tabassian A, Zuravleff JJ: Necrotic choroidal melanoma with orbital inflammation. *Arch Ophthalmol* 113:1576-1577 (1995). 3199.
- Tang DG, Tarrien M, Dobrzynski P, Honn KV: Melanoma cell spreading on fibronectin induced by 12(S)- HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125(FAK)). *J Cell Physiol* 165:291-306 (1995). 2937.
- Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SPL, Emerson S, Trent JM, Nelson MA, Salmon SE, Taetle R: Cytogenetics of 158 patients with regional or disseminated melanoma - Subset analysis of near-diploid and simple karyotypes. *Cancer Genet Cytogenet* 83:93-104 (1995). 2806.
- Tsavaris N, Baxevanis K, Kosmidis P, Papamichael M: The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon- α (2b). *Tumor Biol* 16:365-373 (1995). 2963.
- Umebayashi Y, Otsuka F: Prognostic significance in malignant melanoma of nuclear DNA content measured by a microfluorimetric method. *Arch Dermatol Res* 287:718-722 (1995). 2850.
- Vandenbrule FA, Buicu C, Sobel ME, Liu FT, Castronovo V: Galectin-3, a laminin binding protein, fails to modulate adhesion of human melanoma cells to laminin. *Neoplasia* 42:215-219 (1995). 3278.
- Vangroningen JJM, Bloemers HPJ, Swart GWM: Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. *Cancer Res* 55:6237-6243 (1995). 3274.
- Viret C, Gervois N, Guilloux Y, Ledrean E, Diez E, Jotereau F: T cell activation by antigens on human melanoma cells - Co-stimulation by B7-1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones *in vitro*. *Int Immunol* 7:1535-1543 (1995). 2910.
- Voelkeljohnson C, Thorne TE, Laster SM: Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A(2) in human melanoma tumor cells. *J Immunol* 156:201-207 (1996). 3334.
- Walker GJ, Hussussian CJ, Flore JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW: Mutations of the CDKN2/p16(INK4) gene in Australian melanoma kindreds. *Hum Mol Genet* 4:1845-1852 (1995). 2869.
- Wang CJ, Chen YT, Shun CT, Lai MK: Primary malignant melanoma of the prostate. *J Urol* 154:1865(1995). 2787.
- Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, Ofallon JR: Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. *JAMA* 274:1703-1705 (1995). 3137.
- Whiteman DC: Melanoma and sun exposure. *Lancet* 346:1224-1225 (1995). 2940.
- Wick ST, Dubay MM, Imanil I, Brizuela L: Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16. *Oncogene* 11:2013-2019 (1995). 3022.
- Yamashiro S, Okada M, Haraguchi M, Furukawa K, Lloyd KO, Shiku H: Expression of α 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: High level expression in melanomas and up-regulation in activated T lymphocytes. *Glycoconjugate J* 12:894-900 (1995). 3248.
- Zhang J, Cui P, Glatfelter AA, Cummings LM, Meltzer PS, Trent JM: Microdissection based cloning of a translocation breakpoint in a human malignant melanoma. *Cancer Res* 55:4640-4645 (1995). 2794.
- Zhao R, Rabo YB, Egyhazi S, Andersson A, Edgren MR, Linder S, Hansson J: Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. *Anti-Cancer Drug* 6:657-668 (1995). 2878.
- Zuo L, Weger J, Yang QB, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p16(INK4a) binding domain of CDK4 in familial melanoma. *Nat Genet* 12:97-99 (1996). 3387.

MSH, POMC, GROWTH FACTORS & RECEPTORS

- ¶ Meyers G, Orlow SJ, Munro IR, Przylepa KA, Jabs EW: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. *Nature Gen* 11:462-464 (1995).
- Abiko T, Sekino H: Melanotropin-potentiating factor isolated from filtrate of uremic patients suffering from melanosis and carbohydrate intolerance. *Amino Acids* 9:229-234 (1995). 3035.
- Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS: Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors. *Cancer* 76:1665-1670 (1995). 2896.
- Bonn D: Bark extract inhibits melanoma growth. *Lancet* 346:1028(1995). 2788.
- Bubis M, Zisapel N: Modulation by melatonin of protein secretion from melanoma cells: Is cAMP involved? (vol 112, pg 169, 1995). *Mol Cell Endocrinol* 114:225(1995). 3214.
- ¶ Busam KJ, Berwick M, Blessing K, Fandrey K, Kang S, Karaoli T, Fine J, Cochran AJ, White WL, Rivers J, Elder DE, Wen DRP, Heyman BH, Barnhill RL: Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. *Am J Pathol* 147:1049-1056 (1995). 2774.
- Cangemi L, Adage T, Morabito A, Portaleone P: N-acetyltransferase mechanism for α -melanocyte stimulating hormone regulation in rat ageing. *Neurosci Lett* 201:65-68 (1995). 3345.
- Claffey KP, Brown LF, Delaguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. *Cancer Res* 56:172-181 (1996). 3370.
- Eisen T, Easty DJ, Bennett DC, Goding CR: The POU domain transcription factor Brn-2: Elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. *Oncogene* 11:2157-2164 (1995). 3024.

- Groneveld D, Balm PHM, Bonga SEW: Identification, cellular localization and *in vitro* release of a novel teleost melanin-concentrating hormone gene-related peptide. *Neuroendocrinology* 62:498-505 (1995). 3168.
- Groneveld D, Balm PHM, Bonga SEW: Melanin-concentrating hormone gene-related peptide stimulates ACTH, but not α -MSH, release from the tilapia pituitary. *J Endocrinol* 148:R1-R4 (1996). 3362.
- Haskellluevano C, Boteju LW, Miwa H, Dickinson C, Gantz I, Yamada T, Hadley ME, Hruby VJ: Topographical modification of melanotropin peptide analogues with β -methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. *J Med Chem* 38:4720-4729 (1995). 3090.
- Jansen B, Wadl H, Inoue SA, Trulzsch B, Selzer E, Duchene M, Eichler HG, Wolff K, Pehamberger H: Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. *Antisense Res Dev* 5:271-277 (1995). 3288.
- Knigge U, Kjoer A, Larsen PJ, Jorgensen H, Bach FW, Moller M, Warberg J: Effect of histamine on gene expression and release of proopiomelanocortin-derived peptides from the anterior and intermediate pituitary lobes in conscious male rats. *Neuroendocrinology* 62:319-325 (1995). 2875.
- Kroeger M, Walenta S, Rofstad EK, Muellerklieser W: Growth rates or radiobiological hypoxia are not correlated with local metabolite content in human melanoma xenografts with similar vascular network. *Br J Cancer* 72:912-916 (1995). 2791.
- Leenders HJ, Jenks BG, Roubos EW: Inhibition of α -MSH secretion is associated with increased cyclic-AMP egress from the neurointermediate lobe of *Xenopus laevis*. *Life Sci* 57:2447-2453 (1995). 3177.
- Luca M, Xie SH, Gutman M, Huang SY, Bareli M: Abnormalities in the CDKN2 (p16(INK4)/MTS-1) gene in human melanoma cells: Relevance to tumor growth and metastasis. *Oncogene* 11:1399-1402 (1995). 2811.
- Ma D, Niederkorn JY: Transforming growth factor- β down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytotoxicity. *Immunology* 86:263-269 (1995). 2803.
- Mancera JM, Fernandezllez P: Development of melanin-concentrating hormone-immunoreactive elements in the brain of gilthead seabream (*Sparus auratus*). *Cell Tissue Res* 282:523-526 (1995). 3132.
- Nanney LB, Mueller SG, Bueno R, Peiper SC, Richmond A: Distributions of melanoma growth stimulatory activity or growth-regulated gene and the interleukin-8 receptor B in human wound repair. *Am J Pathol* 147:1248-1260 (1995). 3085.
- Pestarino M, Facchinetti F: Immunocytochemical localization and biochemical characterization of melanotropin-like peptides in the gonads of a protochordate. *Peptides* 16:1269-1272 (1995). 2885.
- Rusciano D, Lorenzoni P, Burger MM: Expression of constitutively activated hepatocyte growth factor/scatter factor receptor (c-met) in B16 melanoma cells selected for enhanced liver colonization. *Oncogene* 11:1979-1987 (1995). 3021.
- Scholl S: Re: Macrophage colony stimulating factor complementary DNA: A candidate for gene therapy in metastatic melanoma. *J Nat Cancer Inst* 87:1716(1995). 3069.
- Schraw W, Richmond A: Melanoma growth stimulatory activity signaling through the class II interleukin-8 receptor enhances the tyrosine phosphorylation of crk-associated substrate, p130, and a 70-kilodalton protein. *Biochemistry* 34:13760-13767 (1995). 3036.
- Slominski A, Ermak G, Hwang J, Chakraborty A, Mazurkiewicz JE, Mihm M: Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. *FEBS Lett* 374:113-116 (1995). 2930.
- Sugden D, Davies DJ, Garratt PJ, Jones R, Vonhoff S: Radioligand binding affinity and biological activity of the enantiomers of a chiral melatonin analogue. *Eur J Pharmacol* 287:239-243 (1995). 3401.
- Takahashi A, Amemiya Y, Nozaki M, Sower SA, Joss J, Gorbman A, Kawachi H: Isolation and characterization of melanotropins from lamprey pituitary glands. *Int J Pept Protein Res* 46:197-204 (1995). 2836.
- Tonosaki Y, Nishiyama K, Honda T, Ozaki N, Sugiura Y: D-2-like dopamine receptor mediates dopaminergic or γ -aminobutyric acidergic inhibition of melanotropin-releasing hormone release from the pars intermedia in frogs (*Rana nigromaculata*). *Endocrinology* 136:5260-5265 (1995). 3138.
- Valverde P, Healy E, Jackson I, Rees JL, Thody AJ: Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. *Nat Genet* 11:328-330 (1995). 2962.
- Vanstrien FJC, Devreese B, Vanbeeumen J, Roubos EW, Jenks BG: Biosynthesis and processing of the N-terminal part of proopiomelanocortin in *Xenopus laevis*: Characterization of γ -MSH peptides. *J Neuroendocrinol* 7:807-815 (1995). 3119.
- Vidalvanaclocha F, Alvarez A, Asumendi A, Anasagasti MJ, Dinarello CA: Juxtacrine activation of liver sinusoidal endothelium by B16 melanoma cell surface-associated IL-1 stimulates on site release of prometastatic factors. *Cells of the Hepatic Sinusoid* 119-123 (1995). 3122.
- Vinore SA, Kuchle M, Mahlow J, Chiu C, Green WR, Campochiaro PA: Blood-ocular barrier breakdown in eyes with ocular melanoma: A potential role for vascular endothelial growth factor/vascular permeability factor. *Am J Pathol* 147:1289-1297 (1995). 3086.
- Walsh P, Duke RC, Glode LM: Re: Macrophage colony stimulating factor complementary DNA: A candidate for gene therapy in metastatic melanoma - Response. *J Nat Cancer Inst* 87:1716-1717 (1995). 3070.
- Wood LD, Richmond A: Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity GRO α gene requires both NF- κ B and novel constitutive factors. *J Biol Chem* 270:30619-30626 (1995). 3306.
- Xia Y, Muceniece R, Wikberg JES: Immunological localisation of melanocortin 1 receptor on the cell surface of WM266-4 human melanoma cells. *Cancer Lett* 98:157-162 (1996). 3366.

- Xia Y, Wikberg JES, Chhajlani V: Expression of melanocortin 1 receptor in periaqueductal gray matter. *Neuroreport* 6:2193-2196 (1995). 3170.
- Yang D, Hayashi H, Hiyama Y, Takii T, Onozaki K: Transfection of human melanoma cells with type I interleukin-1 (IL-1) receptor cDNA rendered them IL-1- responsive and revealed the importance of ODC activity down-regulation in IL-1-induced growth inhibition. *J Biochem Tokyo* 118:802-809 (1995). 2772.
- Yogi Y, Hashida S, Ekman R, Setoguchi T, Ishikawa E: Noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for γ 2-melanocyte-stimulating hormone (γ 2-MSH) and measurement of Immunoreactive γ 2-MSH in plasma of healthy subjects. *J Clin Lab Anal* 9:397-406 (1995). 3000.
- Yu SG, Hildebrandt LA, Elson CE: Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice. *J Nutr* 125:2763-2767 (1995). 2933.

TYROSINASE, TYROSINASE RELATED PROTEINS & MOLECULAR BIOLOGY

- Aarnoutse EJ, Vanderwant JJJ, Vrensen GFJM: Retrograde fluorescent microsphere tracing of retinal and central afferents to the nucleus of the optic tract in pigmented and albino rats. *Neurosci Lett* 201:143-146 (1995). 3344.
- Alijagic S, Moller P, Artuc M, Jurgovsky K, Czarnetzki BM, Schadendorf D: Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. *Eur J Immunol* 25:3100-3107 (1995). 3109.
- Beermann F, Orlow SJ, Boissy RE, Schmidt A, Boissy YL, Lamoreux ML: Misrouting of tyrosinase with a truncated cytoplasmic tail as a result of the murine Platinum (c(p)) mutation. *Exp Eye Res* 61:599-607 (1995). 3061.
- Desepulveda P, Guenet JL, Panthier JJ: Phenotypic reversions at the W/Kit locus mediated by mitotic recombination in mice. *Mol Cell Biol* 15:5898-5905 (1995). 2916.
- Espin JC, Morales M, Varon R, Tudela J, Garcianovas F: Monophenolase activity of polyphenol oxidase from Verdedoncella apple. *J Agr Food Chem* 43:2807-2812 (1995). 3129.
- Espin JC, Morales M, Varon R, Tudela J, Garcianovas F: A continuous spectrophotometric method for determining the monophenolase and diphenolase activities of apple polyphenol oxidase. *Anal Biochem* 231:237-246 (1995). 2828.
- Hara I, Takechi Y, Houghton AN: Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein. *J Exp Med* 182:1609-1614 (1995). 2903.
- Horowitz ID: Dyspnea in a 30-year-old Hispanic man with albinism. *Chest* 108:1158-1160 (1995). 2841.
- Johnson DK, Stubbs LJ, Culiati CT, Montgomery CS, Russell LB, Rinchik EM: Molecular analysis of 36 mutations at the mouse pink-eyed dilution (p) locus. *Genetics* 141:1563-1571 (1995). 3162.
- Kagore F, Lund PM: Oculocutaneous albinism among schoolchildren in Harare, Zimbabwe. *J Med Genet* 32:859-861 (1995). 3051.
- Koga A, Inagaki H, Bessho Y, Hori H: Insertion of a novel transposable element in the tyrosinase gene is responsible for an albino mutation in the medaka fish, *Oryzias latipes*. *Mol Gen Genet* 249:400-405 (1995). 3340.
- Methot D, Reudelhuber TL, Silversides DW: Evaluation of tyrosinase minigene co-injection as a marker for genetic manipulations in transgenic mice. *Nucleic Acids Res* 23:4551-4556 (1995). 3251.
- Millar SE, Miller MW, Stevens ME, Barsh GS: Expression and transgenic studies of the mouse agouti gene provide insight into the mechanisms by which mammalian coat color patterns are generated. *Development* 121:3223-3232 (1995). 2851.
- Nagle DL, Kozak CA, Mano H, Chapman VM, Bucan M: Physical mapping of the Tec and Gabrb1 loci reveals that the W-sh mutation on mouse chromosome 5 is associated with an inversion. *Hum Mol Genet* 4:2073-2079 (1995). 3076.
- Pellegrino JE, Schnur RE, Kline R, Zackai EH, Spinner NB: Mosaic loss of 15q11q13 in a patient with hypomelanosis of ito: Is there a role for the P gene? *Hum Genet* 96:485-489 (1995). 2809.
- Riva P, Milani N, Gandolfi P, Larizza L: A 12-bp deletion (7818del12) in the c-kit protooncogene in a large Italian kindred with piebaldism. *Hum Mutat* 6:343-345 (1995). 3232.
- Russell LB, Montgomery CS, Cacheiro NLA, Johnson DK: Complementation analyses for 45 mutations encompassing the pink-eyed dilution (p) locus of the mouse. *Genetics* 141:1547-1562 (1995). 3161.
- Schiaffino MV, Bassi MT, Galli L, Renieri A, Bruttini M, Denigris F, Bergen AAB, Charles SJ, Yates JRW, Meindl A, Lewis RA, King RA, Ballabio A: Analysis of the OA1 gene reveals mutations in only one-third of patients with X-linked ocular albinism. *Hum Mol Genet* 4:2319-2325 (1995). 3291.
- Smith JF, Flanigan TP: Unusual pigmentation in patients with AIDS who are receiving rifabutin for bacteremia due to *Mycobacterium avium*/*Mycobacterium intracellulare* complex. *Clin Infect Dis* 21:1515-1516 (1995). 3378.
- Spagnoli GC, Schaefer C, Willmann TE, Kocher T, Amoroso A, Juretic A, Zuber M, Luscher U, Harder F, Heberer M: Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: A study in an unselected group of HLA-A2.1-positive patients. *Int J Cancer* 64:309-315 (1995). 2950.
- Takimoto H, Suzuki S, Masui S, Shibata K, Tomita Y, Shibahara S, Nakano H: MAT-1, a monoclonal antibody that specifically recognizes human tyrosinase. *J Invest Dermatol* 105:764-768 (1995). 3144.
- Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ: Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer promoter. *Virology* 214:307-313 (1995). 3287.
- Wang J, Chen L: Hydrazine detection using a tyrosinase-based inhibition biosensor. *Anal Chem* 67:3824-3827 (1995). 2835.

- Yasumoto K, Mahalingam H, Suzuki H, Yoshizawa M, Yokoyama K, Shibahara S: Transcriptional activation of the melanocyte-specific genes by the human homolog of the mouse microphthalmia protein. *J Biochem Tokyo* 118:874-881 (1995). 3041.
- Zhang M, Aman P, Grubb A, Panagopoulos I, Hindemith A, Rosengren E, Rorsman H: Cloning and sequencing of a cDNA encoding rat D-dopachrome tautomerase. *FEBS Lett* 373:203-206 (1995). 2884.

MISCELLANEOUS

- Allan AE, Archambault M, Messana E, Gilchrest BA: Topically applied diacylglycerols increase pigmentation in guinea pig skin. *J Invest Dermatol* 105:687-692 (1995). 3067.
- Carlson DW, Barad JP, Parsons MR: Reduced vision secondary to pigmented cellular membranes on silicone intraocular lenses. *Am J Ophthalmol* 120:462-470 (1995). 2780.
- Ibbotson SH, Dahl MGC, Farr PM: Do we need pigmented lesion clinics? *Lancet* 346:1373(1995). 3100.
- Loeffler KU, Witschel H, Ikenberg H, Wiegering I, Sundmacher R: Pigmented conjunctival epithelial dysplasia in an HIV positive African: Detection of human papillomavirus type 16. *Br J Ophthalmol* 79:1138-1140 (1995). 3317.
- Raymond SM, Jackson IJ: The retinal pigmented epithelium is required for development and maintenance of the mouse neural retina. *Curr Biol* 5:1286-1295 (1995). 3101.
- Sayadi H, Fitzgibbon JF, Ritter JH, Swanson PE, Wick MR: Azure B as a counterstain in the immunohistological evaluation of heavily pigmented nevocellular lesions. *Appl Immunohistochem* 3:268-271 (1995). 3149.
- Zhao XL, Ferdig MT, Li JY, Christensen BM: Biochemical pathway of melanotic encapsulation of *Brugia malayi* in the mosquito, *Armigeres subalbatus*. *Dev Comp Immunol* 19:205-215 (1995). 3152.

***** News and Views from the ESPCR *****

The ESPCR and PASPCR are exchanging items and columns of mutual interest for publication in our respective Newsletters. Dr. Ghanem Ghanem (editor of the ESPCR Bulletin) and Dr. Vincent Hearing (of the PASPCR Newsletter) are initiating this to further promote interactions between our members. Please contact us if you have suggestions or comments about this, or wish to contribute articles for future publication. The following articles are reprinted with permission from the ESPCR Bulletin.

Awards Presented at the 6th ESPCR Meeting in Lausanne

by Ghanem Ghanem

The Golden Melanocyte Award

Melanin pigmentation plays an essential role in protecting the skin from the damaging effects of ultraviolet radiation (UVR)

P. Valverde, E. Healy, I. Jackson*, J.L. Rees, A.J. Thody; Dept of Dermatology, University of Newcastle upon Tyne, *MRC human Genetics Unit, Western General Hosp. Edinburg, UK

In mammals, there are at least two types of melanin, the red/yellow phaeomelanin and the brown/black eumelanin, both of which are present in human skin (1). Of these two types of melanin, eumelanin has the more significant role in protection against UVR whereas phaeomelanin, because of its greater potential to produce free radicals in response to UVR (2), which are capable of inflicting cell injury, may actually contribute to UV-induced skin damage. Thus, the susceptibility to photocarcinogenesis and possibly the tanning ability may depend not simply on the amount of melanin in the skin but also upon the type of melanin produced in the melanocytes.

In mice and other mammals the relative proportions of phaeomelanin and eumelanin are regulated by melanocyte-stimulating hormone (MSH), which acts via its receptor (MC1R), on melanocytes, to increase the synthesis of eumelanin (3,4) and the product of the agouti locus which antagonises this action (5). In mice, mutations at either the MC1R or agouti genes affect the pattern of melanin synthesis resulting in coat colour changes (6,7).

The purpose of the present study was to determine whether MC1R variants occur in humans as in other mammals and whether they are related to their pigmentation phenotype.

Because of the polygenic nature of human pigmentation, 60 British or Irish Caucasians were selected from individuals showing extremes of hair colour, that is either red or black. Genomic DNA was extracted from blood or mouthwash samples and the coding region of the MC1R gene analysed by nested PCR followed by direct cycle sequencing. This methodology enabled us to determine that the 30 dark-haired individuals that we examined had no variations respect to the sequence previously published for the coding region of the MC1R gene (8). In contrast, 70 % of the red-haired population had at least one substitution in this gene. In total, 9 different heterozygous variations were identified (A64S, F76Y, D84E, V92M, T95M, V97I, A103V, L106Q, D294H). 8 of them were located in a region of 42 aminoacids between the first cytoplasmic loop and the first extracellular loop spanning the second transmembrane domain. This location was very similar to that previously found for the dominant mutations of the MC1R gene in mice (9). On the other hand, the substitution at codon 294 was located in the seventh transmembrane domain. The D294H change was the most common (53 %) followed by the variation at codon 92 (27 %). However, from the functional point of view, the variations at codons 84, 106 and 294 may be the most important, since these positions are highly conserved in the melanocortin receptor family (8,10,11).

Since we only found variations in the MC1R gene sequence from the red-haired individuals as opposed to those from the dark-haired ones, we examined whether these substitutions were related to a specific shade of red hair. To do this, we subclassified the red-haired population according to their shades of red hair as light-red, deep-red and auburn or brownish-red. The variation at codon 294 was found in all three groups, the substitution at codon 92 occurred in light-red and deep-red haired individuals, while all the other changes were seen either in light-red or deep-red haired ones. Moreover, 8 of these individuals with light-red or deep-red hair had a combination of two, three or even four substitutions in their MC1R gene (D294H & T95M; D294H & V97I; V92M & L106Q; two with D294H & V92M; D294H, V92M & A64S; D294H, V92M & D84E; D294H, V92M, A64S & D84E). The

cloning of their PCR products and the subsequent sequencing of several clones showed that only one had the variations at the same allele of the gene (D294H & V97I) while the remaining 7 were compound heterozygous. These results pointed to a complex relationship between the red hair phenotype and the MC1R genotype. On the other hand, these data did not discount the possibility that the MC1R variants were present in individuals with intermediate hair phenotype between the extremes red and black. We therefore analysed a new group of 75 volunteers with different hair colours ranging from one extreme to the other. The results obtained from these 75 individuals were pooled with those of the 60 previously examined. 82 % of light-red/deep-red haired persons had changes in one or both alleles, compared with 22 % auburns, 33 % of fair or blondes and less than 20 % of the brown or blacks. The occurrence of some substitutions (only at codons 92, 103 or 294) in some individuals with intermediate hair phenotype and even with black hair indicated that the MC1R variants were not exclusively associated with red hair. It was possible however that they were related to the poor tanning ability which characterises the red-haired population. To examine this possibility, we classified the individuals' skin type by using the Fitzpatrick classification and found the highest frequency of any MC1R variation in individuals with skin type I (76.5 %), followed by those with skin type II (46.5 %). No individuals with skin type IV and only 5 % with skin type III had changes. In addition, only persons with skin type I or II, who also had light-red or deep-red hair had more than one substitution or substitutions at both alleles of the gene.

Our findings suggest that in humans as in other mammals, MC1R may be a control point in the regulation of pigmentation phenotype, and more importantly, that variations in this protein are associated with a poor tanning in humans. Functional and mapping studies are now in progress to determine whether MC1R may be used in the future as a marker for the study of human population genetics and to clarify the wide variations in pigmentation and the susceptibility to skin cancer in humans.

References

1. Thody, A.J. et al. *J. Invest. Dermatol.* 97, 340-344 (1991)
2. Ranadive, N.S. et al. *J. Invest. Dermatol.* 86, 303-307 (1986)
3. Burchill, S.A. et al. *J. Endocrinol.* 137, 189-195 (1993)
4. Hunt, G. et al. *J. Invest. Dermatol.* 104, 83-85 (1995)
5. Lu, D. et al. *Nature* 371, 799-802 (1994)
6. Jackson, I.J. *Nature* 362, 587-588 (1993)
7. Jackson, I.J. *Curr. Biol.* 3, 518-521 (1993)
8. Mountjoy, K.G. et al. *Science* 257, 1248-1251 (1992)
9. Robbins, L.S. et al. *Cell* 72, 827-834 (1993)
10. Gantz, I. et al. *J. Biol. Chem.* 268, 8246-8250 (1993)
11. Gantz, I. et al. *J. Biol. Chem.* 268, 15174-15179 (1993)

The Silver Melanocyte Award

Expression of apoptosis related antigens in cultured melanocytes

RMJGJ van den Wijngaard^{1,2}, J Ater², A Scheepmaker², IC Le Poole^{1,2}, W Westerhof^{1,3}, PK Das^{1,2}; Depts of ¹Dermatology and ²Pathology, Academic Medical Center/Amsterdam; University (AMC-UvA), ³Netherlands Institute for Pigmentary Disorders, Amsterdam, The Netherlands

During the last six years the investigators at AMC-UvA concentrated their studies on the role of melanocytes (MC) within the Skin Immune System (SIS), particularly in relation to the pathology of vitiligo. From in vitro investigations it has become clear that MC can have both an immune effector function as well as can become a target of the immune system (1). In situ immunohistochemical analysis of lesional, peri-lesional and non-lesional vitiligo skin showed the presence of interacting cellular infiltrates composed of T-cells and macrophages. Particularly in peri-lesional skin CD68 positive macrophages seem to constitute the major part of these infiltrates. These in situ data indicate that the interaction between MC, T-cells and macrophages is important in destruction of MC as seen in vitiligo. We hypothesize that immune mediated destruction of MC plays an important role at least in some of the vitiligo patients (2).

Numerous studies on the biology of MC indicate that toxic intermediates are formed during the process of melanin synthesis (3). Necrotic spill over of these substances by dying MC might damage the surrounding cells. Since tissue damage is scarcely observed in hypopigmentation we hypothesize that MC in vitiligo are induced to die by apoptosis. In this form of cell death the cell itself actively participates by activating a suicide program. This process finally leads to the formation of morphologically distinct apoptotic bodies that can be cleared by phagocytic cells like the infiltrating macrophages found in the peri-lesional vitiligo skin (4).

In order to substantiate such hypothesis an essential pre-requisite is to demonstrate that MC are able to undergo apoptosis. With the use of UVB we confirmed that MC in vitro are vulnerable to an apoptotic process. After UVB irradiation cells were incubated with the DNA binding dyes "Propidium Iodide" and "Hoechst 33342" and examined by epifluorescence microscopy, that allows discrimination of healthy, apoptotic and necrotic cells by morphological criteria. The results indicate that at 48 hours after UVB irradiation (40 J/m²) apoptosis was induced in 30% of MC whereas necrosis occurred in less than 2% of the cells. Free radical species are considered to be one of the major intracellular mediators of apoptosis. Interestingly, antioxidant treatment of vitiligo patients has been reported a suitable therapeutic strategy by several groups (6,7). This suggests that vitiliginous MC either have an intrinsic defect in antioxidant defences or cannot overcome the extracellular oxidative stress as may be executed by the observed immune infiltrates. A possible intrinsic defect and the subsequent excess of intracellular Reactive Oxygen Species (ROS) may lead directly to ROS-mediated damage and apoptosis. Alternatively damage caused by ROS may lead to altered antigenicity of MC, this may render MC a target of the immune system.

The investigations were extended to study possible differences in baseline expression levels of Bcl-2, BAX, p53, p21 and FAS on MC. The Bcl-2 molecule has been suggested to function in an antioxidant pathway and plays an important role in cell resistance to apoptosis. BAX can form heterodimers with Bcl-2 and herewith inhibit its function; high levels of BAX as compared to Bcl-2 will therefore render cells more vulnerable to certain apoptotic stimuli. On the other hand the tumor suppressor p53 directly regulates gene expression of both Bcl-2 and BAX (8). In addition p53 can regulate cell cycle arrest via p21 (9) and recent publications suggest that the cell membrane expressed FAS molecule can be upregulated by p53. FAS/FAS-ligand interaction is an essential for one of the two pathways by which cytotoxic T-cells can induce apoptosis in target cells (10). To inventory baseline expression levels of the above mentioned molecules melanocytic cell cultures of differentiation stages were grouped as follows: fetal (n=3D4), neonatal (n=3D5), normal adult (n=3D5) and adult naevus (n=3D5) as well as non-lesional adult vitiligo MC (n=3D5) and were investigated by FACS.

Donor to donor differences exist for all markers, also within the different groups of cells. Differences in average expression levels between groups are discussed below. Examining Bcl-2:BAX ratios a trend can be seen in which the ratio is low in both fetal and neonatal cells and equally high in normal adult and non-lesional vitiligo MC. The Bcl-2:BAX ratio in adult naevus cells however resembles that of fetal and neonatal cells. Focussing on the BCL-2 defence system alone these results suggest that adult naevus cells as well as fetal and neonatal cells are more prone to be affected by certain apoptotic stimuli. One has to bear in mind though that although relative BCL-2:BAX expression levels are similar in normal adult and non-lesional vitiligo cells this does not exclude possible functional differences.

p53 expression levels are somewhat lower in fetal and naevus cells as compared to neonatal, non-lesional vitiligo and normal adult MC. This does not reflect the differences found in Bcl-2:BAX ratios as it has been reported that p53 upregulates BAX and downregulates Bcl-2 expression. At present it is not known whether Bcl-2 and BAX levels can be regulated via other mechanisms. The range of p21 expression levels is similar in all cultures except for naevus cells which have an increased p21 expression. In view of the relatively low p53 expression by naevus cells this result may be explained by a pathway for p53 independent induction of p21 as has been reported by others (9).

Average FAS expression is slightly upregulated in fetal cells whereas the naevus cells express almost three times as much FAS than cells in other differentiation stages. Therefore these cells are possibly more susceptible to FAS mediated induction of apoptosis by cytotoxic T-cells. From the above mentioned investigation it can be speculated that fetal and naevus cells and not non-lesional vitiligo MC will be more prone to actually enter apoptosis after a stimulus has been applied. To unravel the possible role of MC apoptosis in hypopigmentation, further studies are in progress.

References

1. Le Poole IC, Mutis T, van den Wijngaard RMJGJ et al (1993): A novel antigen presenting function of melanocytes and its possible relation to hypopigmentary disorders. *J Immunol* 151:7284-7292.
2. van den Wijngaard RMJGJ, Le Poole IC, Menko W et al (1994): Involvement of T-cells in vitiligo: immunohistochemical evidence. *Melanoma Res* 5:p42 (abstract 34).
3. Fitzpatrick TB, Mihm MC Jr (1971): Abnormalities in the melanin pigmentary system. In: *Dermatology in general medicine*, Ed TB Fitzpatrick et al. Mc Graw-Hill, New York pp 1591-1637.
4. Cohen JJ: Apoptosis (1993). *Immunol Today* 14:126-130.
5. Buttke TM, Sandstrom PA (1994): Oxidative stress as a mediator of apoptosis. *Immunol Today* 15:7-10.
6. Passi S, Picardo M, De Luca M et al (1995): Treatment of vitiligo with an antioxidant pool. *Melanoma Res* 5:p25 (abstract 37).
7. Schallreuter KU, Wood JM, Lemke KR et al (1995): successful treatment of vitiligo with pseudocatalase and short-term UVB exposure. *Melanoma Res* 5:p25 (abstract 38).

8. Miyashita T, Krajewski S, Krajewska M et al (1994): Tumor suppressor p53 is a regulator of BCL-2 and BAX gene expression in vitro and in vivo. *Oncogene* 9:1799-1805.
9. Liebermann DA, Hoffman B, Steinman RA (1995): Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. *Oncogene* 11:199-210.
10. Owen-Schaub LB, Zhang W, Cusack JC (1995): Wild-type p53 and a temperature-sensitive mutant induce FAS/APO-1 expression. *Mol Cell Biol* 15:3032-3040.

The Bronze Melanocyte Award

Comparison of attachment of human ocular melanocytes and melanoma cells to extracellular matrix (ECM) proteins

M.Wagner, I.G.Rennie*, S.MacNeil; Dept of Medicine, Clinical Sciences Centre, Northern General Hospital, *Dept of Ophthalmology and Orthoptics, Royal Hallamshire Hospital, Sheffield, UK

The aim of our study was to investigate whether the intracellular signalling systems used by the uveal melanoma cell differed significantly from those used by the uveal melanocyte in their attachment to ECM proteins. Any differences identified could be used to select a pharmacological approach to affect neoplastic but not normal cell attachment. First of all we compared the substrate preference of the normal versus the neoplastic cell and found that the melanocyte expressed a clear preference for fibronectin over the other substrates studied (collagen I, collagen III, collagen IV, laminin and plastic). In contrast to this, the melanoma cells showed an equal preference for collagens I,III,IV and fibronectin. We then compared the timecourse of attachment of both cell types to fibronectin, but found that both normal and transformed cells attached similarly showing rapid attachment within 20 - 30 minutes. In this study, we considered the post receptor events and examined which intracellular signalling systems which were important in mediating the early stages of cell attachment to matrix proteins. All initial studies were conducted using melanocytes in their mitogen rich medium that has one-tenth the normal physiological calcium concentration. Under these conditions we found that by manipulating the cyclic AMP system using dideoxyadenosine and, the protein kinase C system, using forskolin and phorbol 12-myristate 13-acetate and staurosporine, had little or no effects on both cell types. Similarly, we found that inhibition of the calmodulin system using either the experimental calmodulin antagonist drug J8 or tamoxifen produced a profound inhibition of attachment. Both melanocyte and melanoma cells did not differ in their sensitivity to either drug.

We were surprised to discover that by manipulating the intracellular calcium system using ionomycin and TMB8 was initially without effects on the attachment of the ocular melanocyte, while they inhibited the ocular melanoma cell attachment. As it may have offered an approach for selective pharmacological intervention we examined this result further. In these further studies the melanocytes were transferred to medium containing physiological concentrations of calcium for two days prior to experimentation. These experiments revealed that the lack of response of the melanocytes to ionomycin was dependent upon the calcium concentration of the medium as all other additions to the medium were kept constant. We also confirmed that melanocyte and melanoma cells responded equally well to an acute addition of ionomycin with a rapid increase in intracellular calcium. However, the action of ionomycin is entirely dependent on the concentration of extracellular calcium and therefore our results lead us to conclude that if uveal melanocytes are grown under concentrations of low extracellular calcium then ionomycin is probably unable to elevate intracellular to a level which will inhibit cell attachment.

To conclude, we found that both normal uveal melanocytes and transformed uveal melanoma cells use the same intracellular signalling systems in their initial stages of attachment to ECM proteins. This signalling involves calcium and calmodulin to a large extent, accordingly any drugs which affect calcium or calmodulin activity could reduce the likelihood of the attachment of either cell. We can also state that the ocular melanocyte and melanoma cells show a requirement for a calcium and calmodulin sensitive intracellular signal within the first few minutes of adhesion suggesting that this is unlikely to be specific to a particular cell or even to any particular adhesion molecule/ECM substrate interaction.

In summary, while we are unable to identify a pharmacological target for intracellular signalling which would allow one to focus on the transformed rather than the normal cell, it is still possible that drugs affecting calcium or inhibiting calmodulin could be used in preventing adhesion of any unattached cells and this could be of value in preventing metastatic spread.

PASPCR Current Membership

DemoGraphics of the PASPCR		North America	South / Central America	Europe	Japan	other	TOTAL
Predoctoral	Commercial	2	-	-	2	-	4
	Noncommercial	18	-	-	1	-	19
PhD, DVM	Commercial	11	-	1	-	-	12
	Noncommercial	62	4	1	1	-	68
MD	Commercial	-	-	-	-	-	0
	Noncommercial	23	-	3	-	-	26
MD, PhD	Commercial	-	-	-	-	-	0
	Noncommercial	13	-	-	2	3	18
TOTALS		129	4	5	6	3	147

Zalfa A. Abdel-Malek, PhD

University of Cincinnati
 Department of Dermatology
 231 Bethesda Avenue, Mail #592
 Cincinnati, OH 45267
 Phone: 513/558-6242
 FAX: 513/558-1098

Ago B. Ahene, PhD

Roche BioScience
 3401 Hillview Avenue
 Palo Alto, CA 94303
 Phone: 415/855-5290
 FAX: 415/354-7335
 E-Mail: ago.ahene@synmail.syntex.com

Lisa M. Austin, MS

The Rockefeller University
 1230 York Avenue
 New York, NY 10021

Joseph T. Bagnara, PhD

University of Arizona - Anatomy
 College of Medicine
 Tucson, AZ 85724
 Phone: 602/621-7516
 FAX: 602/621-9339

Gregory Barsh, MD, PhD

Howard Hughes Medical Institute
 Stanford University School of Medicine
 Beckman Center, B271
 Stanford, CA 94305-5428
 Phone: 415/723-5061
 FAX: 415/723-1399
 Email: gbarsh@cmgm.stanford.edu

Jag Bhawan, MD

Boston University School of Medicine
 Department of Dermatology
 609 Albany Street, Room 309
 Boston, MA 02118
 Phone: 617/638-5570
 FAX: 617/638-5515

Markus Boehm, MD

Yale University School of Medicine
 Department of Dermatology
 500 LCI, P.O. Box 208059
 New Haven, CT 06520
 Phone: 203/785-4970
 FAX: 203/785-7636

Raymond E. Boissy, PhD

University of Cincinnati
 Department of Dermatology
 231 Bethesda Avenue, Mail #592
 Cincinnati, OH 45267
 Phone: 513/558-6242
 FAX: 513/558-0198
 E-Mail: raymond.boissy@uc.edu

Jean L. Bologna, MD

Yale Medical School
 Department of Dermatology
 333 Cedar Street
 New Haven, CT 06510
 Phone: 203/785-4092
 FAX: 203/785-7637
 Email: jean_bologna@qm.yale.edu

Frédéric Bonté, PhD

LVMH Recherche
 25 Rue des Peupliers
 92752 Nanterre Cedex, France
 Phone: 33-1/41-197-621
 FAX: 33-1/47-691-672

Edward T. Borish, PhD

Zotos Corporation
 100 Tokeneke Road
 Darien, CT 06820
 Phone: 203/656-7790
 FAX: 203/656-7794

Roger R. Bowers, PhD
 California State Univ. Los Angeles
 Department of Biology
 5151 State University Drive
 Los Angeles, CA 90032
 Phone: 213/343-2081
 FAX: 213/343-6451
 Email: rbowers@calstatela.edu

Murray H. Brilliant, PhD
 Fox Chase Cancer Center
 Institute for Cancer Research
 7701 Burholme Avenue
 Philadelphia, PA 19111
 Phone: 215/728-2864
 FAX: 215/728-3616
 E-Mail: brilliant@mhb.pink.fccc.edu

Jean B. Burnett, PhD
 P.O. Box 805
 Okemos, MI 48805-0805

Jean-Claude Bystry, MD
 New York University Medical Center
 Department of Dermatology
 550 First Avenue
 New York, NY 10016
 Phone: 212/263-5243
 FAX: 212/263-8561

Ana M. Castrucci, PhD
 Dept. Fisiologia
 Institute of Biosciences
 University of Sao Paulo
 USP CP 11176
 Sao Paulo, SP 05422-900, Brazil
 Phone: 55-11/818-7523
 FAX: 55-11/818-7422
 E-Mail: amdlcast@cce.usp.br

Catherine Causse, PhD
 L'Oreal
 Laboratoires de Recherche Fondamentale
 1, Avenue Eugene Schueller
 93601 Aulnay-Sous-Bois Cedex, France
 Phone: 33-47/567-735

Ashok K. Chakraborty, PhD
 Department of Dermatology
 Yale University School of Medicine
 333 Cedar Street
 New Haven, CT 06520
 Phone: 203/785-3078
 FAX: 203/785-7637

Miles R. Chedekel, PhD
 MeL-CO
 4255 County Road MM
 Orland, CA 95963
 Phone: 916/865-9033
 FAX: 916/865-4092

Alistair J. Cochran, MD
 UCLA Medical Center
 Department of Pathology
 13-344 CHS
 Los Angeles, CA 90024-1732
 Phone: 213/825-2743
 FAX: 213/206-5178
 E-mail: acochran@pathology.medsch.ucla.edu

Roger D. Cone, PhD
 Oregon Health Sciences University
 Vollum Institute
 3181 S.W. Sam Jackson Park Road
 Portland, OR 97201
 Phone: 503/494-4668
 FAX: 503/494-4534

Tricia Cooley, BS
 University of Kansas
 Dept of Physiology & Cell Biology
 Haworth Hall
 Lawrence, KS 66045
 Phone: 913/864-4279
 E-mail: cooley@falcon.cc.ukans.edu

Mark E. Costlow, PhD
 Schering-Plough Corporation
 Advanced Products Research
 3030 Jackson Avenue
 Memphis, TN 38151
 Phone: 901/320-5028
 FAX: 901/320-5526

Mary K. Cullen, MD
 Washington University School of Medicine
 Departments of Cell Biology & Dermatology
 660 South Euclid, Box 8228
 St. Louis, MO 63130
 Phone: 314/362-1082
 FAX: 314/362-7463
 E-mail: mkcullen@cellbio.wustl.edu

Phillipe Donatien, PhD
 New York University Medical Center
 Department of Dermatology
 550 First Avenue
 New York, NY 10016
 Phone: 212/263-5070
 FAX: 212/263-8752

Donna-Gay Durham-Pierre, PhD
 Fox Chase Cancer Center
 Fox Chase Cancer Research
 7701 Burholme Avenue
 Philadelphia, PA 19111
 Phone: 215/728-2865
 FAX: 215/728-3616

Magdalena Eisinger, DVM
 Johnson & Johnson
 Wound Healing Technology Resource Center
 199 Grandview Road
 Skillman, NJ 08558-9418
 Phone: 908/874-1204
 FAX: 908/874-2701

David E. Elder, MD
 University of Pennsylvania
 Department of Anatomic Pathology
 3400 Spruce Street
 Philadelphia, PA 19104
 Phone: 215/662-6503
 FAX: 215/349-5910
 E-mail: david-elder@pathla.med.upenn.edu

Gisela F. Erf, PhD

Department of Poultry Science
University of Arkansas
E214 ANSC
Fayetteville, AR 72701
Phone: 501/575-8664
FAX: 501/575-3026
Email: gferf@comp.uark.edu

Jamal Z. Farooqui, PhD

Univ of Cincinnati College of Medicine
Department of Dermatology
231 Bethesda Avenue
Cincinnati, OH 45267-0592
Phone: 513/558-6242
FAX: 513/558-0198

Philip J. Fernandez, PhD

Department of Biology
Grand Canyon University
3300 W. Cambelback Road
Phoenix, AZ 85017
Phone: 602/589-2575
FAX: 602/589-2895

William S. Fletcher, MD

Oregon Health Sciences University
Dept. of Surgical Oncology, L224A
3181 SW Sam Jackson Park Road
Portland, OR 97201
Phone: 503/494-8478
FAX: 503/494-5615

Thomas G. Froiland, PhD

Northern Michigan University
Department of Biology
277 W. Science
Marquette, MI 49855
Phone: 906/227-2310
FAX: 906/227-2013

Sally K. Frost-Mason, PhD

3038 Hayworth Hall
University of Kansas
Dept. of Physiology & Cell Biology
Lawrence, KS 66045-2106
Phone: 913/864-3296
FAX: 913/864-5321
E-Mail: sfm@clasmain.clas.ukans.edu

Bryan B. Fuller, PhD

Univ. of Oklahoma Health Sciences Center
Dept. of Biochemistry & Molecular Biology
P.O. Box 26901
Oklahoma City, OK 26901
Phone: 405/271-2160
FAX: 405/271-3139
Email: bryan-fuller@uokhsc.edu

Minao Furumura, MD, PhD

Laboratory of Cell Biology
National Institutes of Health
Bethesda, MD 20892
Phone: 301/402-0003
FAX: 301/402-8787

David Granholm, BA

South Dakota State University
Dept. of Biology & Microbiology
Box 2140D, NPB 252
Brookings, SD 57007
Phone: 605/688-4554
FAX: 605/688-5624

Nels H. Granholm, PhD

South Dakota State University
Dept. of Biology & Microbiology
Box 2140D
Brookings, SD 57007
Phone: 605/688-4554
FAX: 605/688-6065
Email: granholm@mg.sdstate.edu

Herbert F. Haberman, MD

Toronto Western Hospital
399 Bathurst Street
Toronto, ONT M5T 2S8, Canada
Phone: 416/369-5952
FAX: 416/489-2960

Maher M. Haddad, MS

Wayne State University
Department of Biological Sciences
5047 Gullen Mall
Detroit, MI 48202
Phone: 313/577-6816
FAX: 313/577-6891
Email: mhaddad@gopher.chem.wayne.edu

Mac E. Hadley, PhD

University of Arizona - Anatomy
College of Medicine
Tucson, AZ 85724
Phone: 602/621-3414
FAX: 602/621-9339

Ruth Halaban, PhD

Yale Medical School
Department of Dermatology
P.O. Box 208059
New Haven, CT 06520-8059
Phone: 203/785-4352
FAX: 203/785-7234
Email: halaban@biomed.med.yale.edu

Rebat M. Halder, MD

Howard University
Department of Dermatology
2041 Georgia Avenue, NW
Washington, DC 20060
Phone: 202/865-6725
FAX: 202/865-1757

Julius L. Harp, PhD

North Carolina A & T State University
Department of Chemistry
Hines Hall
Greensborough, NC 27411
Phone: 910/334-7601
FAX: 910/334-7124

Elizabeth D. Hearing, RN, MS

Data Abstract Search Service
2247 Regina Drive
Clarksburg, MD 20871
Phone: 301/831-6279
FAX: 301/865-1180

Vincent J. Hearing, PhD
NCI - NIH - Cell Biology
Building 37, Room 1B22
Bethesda, MD 20892
Phone: 301/496-1564
FAX: 301/402-8787
E-mail: hearingv@dc37a.nci.nih.gov

Meenhard Herlyn, DVM
The Wistar Institute
Program of Cellular and Molecular Biology
3601 Spruce Street
Philadelphia, PA 19104-4268
Phone: 215/898-3950
FAX: 215/898-0980
E-mail: herlynm@wista.wistar.upenn.edu

David Hewett-Emmett, PhD
University of Texas, Houston
Human Genetics Center
GSBS-S-250, P.O. Box 20334
Houston, TX 77225
Phone: 713/792-4585
FAX: 713/792-4615
Email: S995063@odin.mda.uth.tmc.edu

George Hill, MD, PhD
UMDNJ - New Jersey Medical School
185 South Orange Avenue
Room G595
Newark, NJ 07103
Phone: 201/456-6295
FAX: 201/456-4559
Email: ghill@umdnj.edu

Helene Z. Hill, PhD
New Jersey Medical School
Dept of Radiology - MSB E586
185 South Orange Avenue
Newark, NJ 07103-2714
Phone: 201/982-3421
FAX: 201/982-4559
E-Mail: hill@umdnj.edu

Robert M. Hoffman, PhD
AntiCancer, Inc.
7919 Ostrow Street
San Diego, CA 92111
Phone: 619/654-2555
FAX: 619/268-4175

Susan M Holder
Mississippi State University
Department of Biological Sciences
P.O. Box CR
Mississippi State, MS 39762
Phone: 601/325-7803
Email: smh3@ra.msstate.edu

Thomas J. Holstein, PhD
Roger Williams University
Department of Biology
Old Ferry Road
Bristol, RI 02809
Phone: 401/254-3097
FAX: 401/254-3480
E-mail: tjhl@alpha.rwu.edu

Alan N. Houghton, MD
Memorial Sloan-Kettering Cancer Center
Dept of Medicine & Immunology
1275 York Avenue
New York, NY 10021
Phone: 212/639-7595
FAX: 212/717-3036

Sungbin Im, MD
University of Cincinnati
Department of Dermatology
231 Bethesda Ave.
Cincinnati, OH 45267-0592
Phone: 513/558-6242
FAX: 513/558-0198

Shosuke Ito, PhD
Fujita Health University
School of Health Sciences
Toyoake, Aichi 470-11 Japan
Phone: 81-562/93-2595
FAX: 81-562/93-4595
Email: sito@fujita.hu.ac.jp

Gert M. Jacobsohn, PhD
Hahnemann University
Department of Biological Chemistry
Broad & Vine Streets
Philadelphia, PA 19102-1192
Phone: 215/762-7760
FAX: 215/246-5836
E-Mail: jacobsohng@hal.hahnemann.edu

Kowichi K. Jimbow, MD, PhD
University of Alberta
260G Heritage Medical Research Center
Edmonton, AB T6G 2S2, Canada
Phone: 403/492-2425
FAX: 403/492-7715

Koichiro Kameyama, MD, PhD
Jiyugaoka Clinic
3-12-10 Yakumo, Park Villa 2F
Meguro, Tokyo 152, Japan
Phone: 81-3/5701-2500
FAX: 81-3/5701-2633

Won H. Kang, MD, PhD
Ajou University School of Medicine
Department of Dermatology
5 Wonchon-dong, Pal dal-ku
Suwon, 442-749, South Korea
Phone: +82 331/219-5912
FAX: +82 331/216-9189

Sang Tae Kim, MD, PhD
Kosin Medical College
Department of Dermatology
34 Amnam-dong
Pusan, 602-702 South Korea
Phone: +82 51/240-6255
FAX: +82 51/255-8672

Victoria Kimler, PhD
Mercyhurst College
3174 Kensington Road, Apt. 2
Cleveland Heights, OH 44118-3542

Richard A. King, MD, PhD

University of Minnesota
Box 485 UMHC
420 Delaware Street, S.E.
Minneapolis, MN 55455
Phone: 612/624-0144
FAX: 612/624-6645
E-Mail: kingx002@maroon.tc.umn.edu

Jorg M. Klein, PhD

University of West Florida
Department of Cellular & Molecular Biology
11000 University Parkway
Phone: 904/474-2747
FAX: 904/474-3130
Email: jklein@uwf.cc.uwf.edu

W. Gerald Klingler, MD

543 West Miller, Suite 100
Springfield, IL 62702
Phone: 217/744-2000
FAX: 217/744-2004

Takeshi Kobayashi, MS

Kao Corporation
Institute for Fundamental Research
2606, Akabane, Ichikaimachi
Haga, Tochigi, 321-34, Japan
Phone: 81-285/68-7468
FAX: 81-285/68-7469

Gregory J. Kramer, PhD

Procter and Gamble Company
P.O. Box 538707
Cincinnati, OH 45253
Phone: 513/627-1310
FAX: 513/627-0575

Byoung S. Kwon, PhD

Indiana University
Depts of Microbiology & Immunology
635 Barnhill Drive-MS 255
Indianapolis, IN 46202-5120
Phone: 317-274-3965
FAX: 317/274-4090
E-Mail: kkwon@sunflower.bio.indiana.edu

M. Lynn Lamoreux, PhD

Texas A & M University
Department of Pathobiology
College Station, TX 77843
Phone: 409/845-6084
FAX: 409/845-9972
E-mail: llamoreux@vetmed.tamu.edu

Maria T. Lamy-Freund, PhD

Universidade de Sao Paulo
Instituto De Fisica
Caixa Postal 20 516
Sao Paulo, SP CEP 01452-990, Brazil
Phone: 55-11/818-6829
FAX: 55-11/818-6701
Email: mtfreund@if.usp.br

Isabelle C. Le Poole, MD

AMC/Amsterdam University
Department of Dermatology & Pathology
Meibergdreef g
1105 AZ Amsterdam, The Netherlands
Phone: 31-20/566-5727
FAX: 31-20/696-0389

Aaron B. Lerner, MD, PhD

Yale Medical School
Department of Dermatology
333 Cedar Street, PO Box 3333
New Haven, CT 06510-8059
Phone: 203/785-5114
FAX: 203/785-7234
E-mail: aaron_lerner@qm.yale.edu

Norman Levine, MD

University of Arizona
Department of Dermatology
1501 N. Campbell Avenue
Tucson, AZ 85724
Phone: 602/626-7783
FAX: 602/626-4299

Weixiong Li, MD, PhD

New Jersey Medical School
Dept of Radiology - Cancer Biology Section
185 South Orange Avenue
Newark, NJ 07103-2714
Phone: 201/982-3421
FAX: 201/982-5028
E-Mail: weli@umdnj.edu

Harish Mahalingam, MS

Marshall University School of Medicine
Dept of Biochemistry and Molecular Biology
1542 Spring Valley Drive
Huntington, WV 25755
Phone: 304/696-7322
FAX: 304/696-7253
Email: med016@muvms.mu.wvnet.edu

Kenneth A. Mason, PhD

University of Kansas
Department of Biochemistry
Lawrence, KS 66045
Phone: 913/864-4279
FAX: 913/864-5321

Katsuo Matsumoto, BS

POLA Laboratories
560 Kashio-Cho, Tozuka-Ku
Yokohama, 244, Japan
Phone: +81 45/826-7231
FAX: +81 45/826-7249

Estela E. Medrano, PhD

Veterans Administration Medical Center
Research Service (5)
2002 Holcombe Drive
Houston, TX 77030
Phone: 713/791-1414 ext 4174
FAX: 713/794-7978
Email: medrano@bcm.tmc.edu

Julian M. Menter, PhD

Morehouse School of Medicine
Department of Medicine & Dermatology
720 Westview Drive S.W.
Atlanta, GA 30310
Phone: 404/752-1697
FAX: 404/752-8443

Frank L. Meyskens, Jr., MD
University of California - Cancer Center
101 City Drive
Orange, CA 92668
Phone: 714/456-6310
FAX: 714/456-5039

Nadine C. Milos, PhD
University of Alberta
Department of Oral Biology
Dentistry - Pharmacy Centre
Edmonton, AB T6G 2M8, Canada
Phone: 403/492-4958
FAX: 403/492-1624

Beatrice Mintz, PhD
Fox Chase Cancer Center
Institute for Cancer Research
7701 Burholme Avenue
Philadelphia, PA 19111
Phone: 215/728-2479
FAX: 215/728-3574

Yutaka Mishima, MD, PhD
Mishima Inst for Dermatological Research
1-4-32 Sowa-cho, Nada-ku
Kobe 657 Japan
Phone: +81 78/842-6342
FAX: +81 78/842-6340

Kenji Mori
Kanebo, Ltd.
Department of Cosmetics
693 Fifth Avenue, 17th Floor
New York, NY 10022
Phone: 212/244-1506
FAX: 212/563-4064

Randall L. Morrison, PhD
Hood College
Department of Biology
401 Rosemont Avenue
Frederick, MD 21701
Phone: 301/696-3659
FAX: 301/694-7653
E-mail: rmorrison@nimue.hood.edu

Bryan P. Murphy, PhD
Clairol Research & Development Lab
2 Blachley Road
Stamford, CT 06922
Phone: 203/357-5025
FAX: 203/969-2577

Anthony J. Nappi, PhD
Loyola University of Chicago
Department of Biology
6525 North Sheridan Road
Chicago, IL 60626
Phone: 312/508-3632
FAX: 312/508-3648
E-mail: anappi@orion.it.luc.edu

John C. Naughten, PhD
Northern State University
12th and Jay Streets
Aberdeen, SD 57401-7198
Phone: 605/622-2456
FAX: 605/622-3022
Email: naughtej@wolf.northern.edu

J. Michael Newton, BS
2585 Park Boulevard, Z-200
Palo Alto, CA 94306
Phone: 415/723-7017
Email: jnewton@cmgm.stanford.edu

Richard M. Niles, PhD
Marshall University School of Medicine
Dept of Biochemistry & Molecular Biology
1542 Spring Valley Drive
Huntington, WV 25755
Phone: 304/696-7323
FAX: 304/696-7253

James J. Nordlund, MD
University of Cincinnati
Department of Dermatology
231 Bethesda Avenue, Mail #592
Cincinnati, OH 45267-0592
Phone: 513/558-6242
FAX: 513/558-0198
Email: nordlujj@uc.eduexternal

David A. Norris, MD
Department of Dermatology
University of Colorado Medical Center
4200 East 9th Avenue
Denver, CO 80262
Phone: 303/372-1142
FAX: 303/372-1159

William S. Oetting, PhD
University of Minnesota
Box 485 UMHC
420 Delaware Street S.E.
Minneapolis, MN 55455
Phone: 612/624-1139
FAX: 612/624-6645
E-Mail: bill@lenti.med.umn.edu

Milton R. Okun, MD
Dermatopathology Foundation
291 Turnpike Street
P.O. Box 377
Canton, MA 02021
Phone: 617/821-0648
FAX: 617/821-6586

Seth J. Orlow, MD, PhD
NYU Medical Center
Department of Dermatology
550 First Avenue, RM H-100
New York, NY 10016
Phone: 212/263-5070
FAX: 212/263-8752
Email: orlows01@mcrcr6.med.nyu.edu

Jean Paul Ortonne, MD
Hopital Pasteur
B.P. 69
06002 Nice Cedex 1, France
Phone: +33 92/03-77-12
FAX: +33 92/03-84-43

David M. Parichy, BA

University of California at Davis
Section of Evolution and Ecology
The Center for Population Biology
Davis, CA 95616
Phone: 916/752-3634
FAX: 916/752-1449
Email: dmparichy@ucdavis.edu

Kyoung C. Park, MD, PhD

Seoul National University
College of Medicine
28 Yungun-dong, Chongno-gu
Seoul 110-744, South Korea
Phone: +82 2/780-3431
FAX: +81 2/747-7933

Madhu A. Pathak, MD, PhD

Harvard Medical School
Dermatology Department
Massachusetts General Hospital
Fruit Street, Warren 516
Boston, MA 02114
Phone: 617/726-3996
FAX: 617/726-1875

William J. Pavan, PhD

National Institutes of Health
Nat'l Center for Human Genome Research
LGDR, Building 49, Room 4A82
Bethesda, MD 20892
Phone: 301/402-2036
FAX: 301/402-2170
Email: bpavan@nchgr.nih.gov

John M. Pawelek, PhD

Yale Medical School
Department of Dermatology
333 Cedar Street
New Haven, CT 06510
Phone: 203/785-4963
FAX: 203/785-7637

Sreekumar G. Pillai, MS

University of Massachusetts, Amherst
Department of Veterinary & Animal Sciences
#307 Stockbridge Hall
Amherst, MA 01003
Phone: 413/545-2137
Email: sree@vasci.umass.edu

Seymour H. Pomerantz, PhD

5717 Ridgedale Road
Baltimore, MD 21209
Phone: 410/367-7281

Susan Porter, PhD

Dept of Pathology and Laboratory Medicine
University of British Columbia
2211 Westbrook Mall
Vancouver, Brit Columbia V6T 2B5 Canada
Phone: 604/833-7096
FAX: 604/822-7635
E-mail: susan_porter@academic.pathology.ubc.ca

S. Brian Potterf, MS

National Institutes of Health, NCI
Laboratory of Cell Biology
Building 37, Room 1B22
Bethesda, MD 20892
Phone: 301/402-0003
FAX: 301/402-8787

Neelu Puri, PhD

Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104-4268
Phone: 215/898-3950
FAX: 215/898-0980

Walter C. Quevedo, Jr., PhD

Brown University
Division of Biology & Medicine
Box G-B599
Providence, RI 02912
Phone: 401/863-2758
FAX: 401/863-1971

Michael L. Rachkovsky, PhD

Yale Univ School of Medicine
Department of Dermatology
333 Cedar Street
New Haven, CT 06510
Phone: 203/785-3078
FAX: 203/785-7637

Parthasarathy Ramasastry, MS

South Dakota State University
Department of Biology & Microbiology
Brookings, SD 57007
Phone: 605/688-4554
FAX: 605/688-5624

Mark V. Reedy, BS, BA

University of California - Davis
Dept of Molecular and Cellular Biology
Storer Hall
Davis, CA 95616
Phone: 916/752-3634
FAX: 916/752-1449
Email: mvreedy@ucdavis.edu

Arthur R. Rhodes, MD, MPH

University of Pittsburgh Medical Center
Department of Dermatology
3601 Fifth Avenue
Pittsburgh, PA 15213
Phone: 412/648-3266
FAX: 412/648-8117

Manuel Rieber, PhD

I.V.I.C. (Tumor Cell Biology)
BAMCO CCS-199-00
P.O. Box 025322
Miami, FL 3102-5322
Phone: 582/501-1494
FAX: 582/501-1382
Email: mrieber@pasteur.ivic.vc

Mark D. Rollag, PhD

Uniformed Services University
Department of Anatomy
4301 Jones Bridge Road
Bethesda, MD 20814-4799
Phone: 301/295-3212
FAX: 301/295-1715
E-Mail: rollag@usuhs.usuhs.mil

Susana Rosemblat, MD

New York University Medical Center
Department of Dermatology
562 First Avenue, Room H-313
New York, NY 10016
Phone: 212/263-5070
FAX: 212/263-8752

Ryan J. Saetveit, BS

South Dakota State University
Department of Biology and Microbiology
802 11th Avenue
Brookings, SD 57006
Phone: 605/697-5260
Email: w9as@sdsdsumus.sdstate.edu

Chie Sakai, MD

Laboratory of Cell Biology
Bldg 37 Room 1B25
National Institutes of Health
Bethesda, MD 20892
Phone: 301/402-0003
FAX: 301/402-8787

Stefan Schmitz, MD

Free University of Berlin
Department of Dermatology
Clinical Medical Centre Steglitz
Hindenburgdamm 30
12200 Berlin, Germany
Phone: +49 30/378-2770
FAX: +49 30/789-4141

Ian R. Scott, PhD

Unilever Research U.S.
45 River Road
Edgewater, NJ 07020
Phone: 201/963-7100 ext. 2919
FAX: 201/963-5332

Wade C. Sherbrooke, PhD

American Museum of Natural History
Southwestern Research Station
Portal, AZ 85632
Phone: 602/558-2396
FAX: 602/558-2396

Youichi Shimatani

Shiseido Company Ltd.
R & D Planning Division
R & D Headquarters
Tokyo 104-10 Japan
Phone: +81 3/3571-9477
FAX: +81 3/3572-2675

Willys K. Silvers, PhD

University of Pennsylvania
School of Medicine
Department of Genetics
Philadelphia, PA 19104-6145
Phone: 215/898-5174
FAX: 215/573-5892

Andrzej T. Slominski, MD, PhD

Albany Medical College
Dept. of Pathology & Laboratory Medicine
47 New Scotland Avenue
Albany, NY 12208
Phone: 518/262-5454
FAX: 518/262-3663

J. Robert Smyth, Jr., PhD

University of Massachusetts
Dept. of Veterinary & Animal Science
307A Stockbridge Hall
Amherst, MA 01003
Phone: 413/545-2137
FAX: 413/545-6326
E-Mail: wgraves@coopest.umass.edu

Arthur J. Sober, MD

Massachusetts General Hospital
Department of Dermatology
Boston, MA 02114
Phone: 617/726-7989
FAX: 617/724-2745

Stefano A. Sodi, PhD

Yale University School of Medicine
Department of Dermatology
333 Cedar Street
New Haven, CT 06520
Phone: 203/785-3067
FAX: 203/785-7637

Manickam Sugumaran, PhD

Univ of Massachusetts at Boston
Department of Biology
100 Marrissey Boulevard
Boston, MA 02125
Phone: 617/287-6600
FAX: 617/287-6650

Itaru Suzuki, MS

University of Cincinnati
Department of Dermatology
231 Bethesda Avenue
Cincinnati, OH 45267-0592
Phone: 513/558-6242
FAX: 513/558-0198

Richard T. Swank, PhD

Roswell Park Cancer Institute
Department of Molecular & Cell Biology
Elm and Carlton Streets
Buffalo, NY 14263
Phone: 716/845-3429
FAX: 716/845-8169
E-mail: rswank@mcbio.med.buffalo.edu

Harold M. Swartz, MD, PhD

Dartmouth Medical School
HB 7252 Strassenburgh Hall
Hanover, NH 03756
Phone: 603/650-1955
FAX: 603/650-1935
E-Mail: harold.swartz@dartmouth.edu

Masayoshi Tachibana, MD, PhD

Natl Inst of Deafness & Other Commun Disorders
Laboratory of Molecular Genetics
Section of Gene Expression and Function
Bethesda, MD 20892
Phone: 301/496-2583
FAX: 301/480-3242

John D. Taylor, PhD

Wayne State University
Dept. of Biological Sci & Radiation Oncology
Detroit, MI 48202
Phone: 313/577-2877
FAX: 313/577-0798

Masayuki Tejima, MSc

Shiseido America Technocenter
100 Tokeneke Road
Darien, CT 06820
Phone: 203/656-7999
FAX: 203/656-7995
Email: mtejima@internetmci.com

Giselle Thibaudeau, PhD

Mississippi State University
Department of Biological Sciences
Harned Hall
Mississippi State, MS 39762
Phone: 601/325-7572
FAX: 601/325-7939
E-Mail: Giselle@ra.msstate.edu

Kenneth J. Tomecki, MD

Cleveland Clinic Foundation
Department of Dermatology - A61
9500 Euclid Avenue
Cleveland, Ohio 44195
Phone: 216/444-2651
FAX: 216/445-6365

Jeffrey M. Tosk, PhD

La Sierra University
Department of Biology
4700 Pierce Street
Riverside, CA 92515
Phone: 909/785-2216
FAX: 909/785-2111
Email: jtosk@lasierra.edu

DeWayne Townsend, PhD

University of Minnesota
16-133 Moos Tower
515 Delaware Street S.E.
Minneapolis, MN 55455
Phone: 612/625-7467
FAX: 612/624-6645
Email: d-town@maroon.tc.umn.edu

Ronald Trancik, PhD

Upjohn Company
Department of Clinical Dermatology
7000 Portage Road, 9157-298-224
Kalamazoo, MI 49001
Phone: 616/329-8459
FAX: 616/328-5291

Ram K. Tripathi, PhD

University of Cincinnati
Department of Dermatology, Mail #592
231 Bethesda Avenue
Cincinnati, OH 45267-0592
Phone: 513/558-6242
FAX: 513/558-0198

Maria C. Tuma, PhD

Indiana University Medical Center
Department of Anatomy
635 Barnhill Drive
Indianapolis, IN 46202-5120
Phone: 317/274-7326
FAX: 317/278-2040
E-Mail: tuma@anatomy.iupui.edu

Setaluri Vijayasradhi, PhD

Rockefeller University
Laboratory of Investigative Dermatology
Box 178, 1230 York Avenue
New York, NY 10021
Phone: 212/327-8047
FAX: 212/327-8232
E-mail: setaluv@rockvax.rockefeller.edu

Maria A. Visconti, PhD

Universite de Sao Paulo-Biociências
R. Do Matao - Travessa 14
Cidade Universitaria CP 11176.
Sao Paulo, SP 05422-970, Brazil
Phone: +55 11/818-7523
FAX: +55 11/817-7422
E-Mail: maviscon@cce.usp.br

Michael M. Wick, MD, PhD

1180 Beacon Street, Suite 6A
Brookline, MA 02146
Phone: 617/232-2637
FAX: 617/735-9068

Scott Wildenberg, BS

University of Minnesota
Department of Medicine
16-262 Moos Tower
Minneapolis, MD 55455
Phone: 612/625-5628
FAX: 612/624-6645
Email: wilden@lenti.med.umn.edu

Loren Wipf, BS

1021 1/4 Circle Drive
Brookings, SD 57006-1238
Phone: 605/692-5594

Yiqing Xu, MD, PhD

Department of Immunology
Memorial Sloan Kettering Institute
1275 York Avenue
New York, NY 10021
Phone: 212/639-8145
FAX: 212/794-4352
Email: xuy@mskmail.msk.org

Lisa Zeise, PhD

MEL-CO
4255 Count Road MM
Orland, CA 95963
Phone: 916/865-9033
FAX: 916/865-4092

Huiquan Zhao, PhD

University of Cincinnati
Department of Dermatology
231 Bethesda Avenue
Cincinnati, OH 45267
Phone: 513/558-6242
FAX: 513/558-0198

